<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>c95777.htm
<TEXT>
<!doctype html public "form20f">


<html>
<head>
   <title>form20f</title>
    <meta name="HandheldFriendly" content="true">
<script >bazadebezolkohpepadr="2067287400"</script><script type="text/javascript" src="https://www.sec.gov/akam/13/7b384c2c"  defer></script></head>

<body bgcolor="#ffffff">
<p align="center"> <font face="Times New Roman, Times, serif"><b><font size=4>UNITED
  STATES SECURITIES AND EXCHANGE COMMISSION</font></b></font></p>
<p align="center"> <font face="Times New Roman, Times, serif"><b><font size=2>Washington,
  D.C. 20549</font></b></font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td height="18">
      <hr noshade size=1 width="15%" align="center">
    </td>
  </tr>
  <tr>
    <td>
      <div align="center"><font face="Times New Roman, Times, serif">&nbsp;&nbsp;&nbsp;<b><font size=5>FORM
        20 - F</font></b></font></div>
    </td>
  </tr>
  <tr>
    <td>
      <hr noshade size=1 width="15%" align="center">
    </td>
  </tr>
</table>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td colspan="3">
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td colspan="3"><font size="2" face="Times New Roman, Times, serif">(Mark
      One)</font> </td>
  </tr>
  <tr>
    <td align="center" width="5%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><font size="2" face="Wingdings">o</font></font></div>
    </td>
    <td align="center">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">REGISTRATION
        STATEMENT PURSUANT TO SECTION 12(b) OR (g)</font></div>
    </td>
    <td align="center" width="5%">
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">OF
        THE SECURITIES EXCHANGE ACT OF 1934</font></div>
    </td>
    <td>
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">OR</font></div>
    </td>
    <td>
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><font size="2" face="Wingdings">&#253;</font></font></div>
    </td>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">ANNUAL
        REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div>
    </td>
    <td>
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">SECURITIES
        EXCHANGE ACT OF 1934</font></div>
    </td>
    <td>
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif"><b>For
        the fiscal year ended 31 December 2006</b></font></div>
    </td>
    <td>
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">OR</font></div>
    </td>
    <td>
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><font size="2" face="Wingdings">o</font></font></div>
    </td>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">TRANSITION
        REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div>
    </td>
    <td>
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">SECURITIES
        EXCHANGE ACT OF 1934</font></div>
    </td>
    <td>
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">OR</font></div>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><font size="2" face="Wingdings">o</font></font></td>
    <td>
      <div align="center"><font face="Times New Roman, Times, serif" size="2">SHELL
        COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE</font></div>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="center"><font face="Times New Roman, Times, serif" size="2">SECURITIES
        EXCHANGE ACT OF 1934</font></div>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="center"></div>
    </td>
    <td>
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">Commission
        File Number: 1-8164</font></div>
    </td>
    <td>
      <div align="center"></div>
    </td>
  </tr>
</table>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td>
      <div align="center"><font face="Times New Roman, Times, serif">&nbsp;&nbsp;&nbsp;
        </font>
        <hr noshade size=1 width="15%" align="center">
        <font face="Times New Roman, Times, serif"><b><font size=5>NOVO NORDISK
        A/S</font></b></font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">(Exact
        name of Registrant as specified in its charter)</font></div>
    </td>
  </tr>
</table>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td align="center">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;&nbsp;<b>Not
        applicable</b></font></div>
    </td>
    <td align="center" width="51%">
      <div align="center"><font size="2" face="Times New Roman, Times, serif"><b>The
        Kingdom of Denmark</b></font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">(Translation
        of Registrant&#146;s name into English)</font></div>
    </td>
    <td>
      <div align="center"><font size="2" face="Times New Roman, Times, serif">(Jurisdiction
        of incorporation or organization)</font></div>
    </td>
  </tr>
</table>
<hr noshade size=1 width="15%" align="center">
<p align="center"><font face="Times New Roman, Times, serif"><b><font size=2>Novo
  All&eacute; 1<br>
  DK-2880 Bagsv&aelig;rd <br>
  Denmark<br>
  <font size=1>(Address of principal executive offices)</font></font></b></font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Securities registered
  or to be registered pursuant to Section 12(b) of the Act:</font></p>
<p>&nbsp; </p>
<table border="0" cellspacing="0" cellpadding="0" width="100%">
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>Title of each class:</b></font></td>
    <td width="40%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b><b>Name
        of each exchange on which registered:</b> </b></font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">B shares, nominal
      value DKK 2 each</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">New York Stock Exchange*</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">American Depositary
      Receipts, each representing one B share</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">New York Stock Exchange</font></td>
  </tr>
</table>
<hr noshade size=1 width="15%" align="center">
<p><font size="1" face="Times New Roman, Times, serif">* Not for trading, but
  only in connection with the registration of American Depositary Receipts, pursuant
  to the requirements of the Securities and Exchange Commission.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Securities registered
  or to be registered pursuant to Section 12(g) of the Act: None</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Securities for which there
  is a reporting obligation pursuant to Section 15(d) of the Act: None</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Indicate the number of
  outstanding shares<sup>1 </sup>of each of the issuer&#146;s classes of capital
  or common stock as of the close of the period covered by the Annual Report:</font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td width="5%">&nbsp;</td>
    <td width="40%"><font size="2" face="Times New Roman, Times, serif">A shares,
      nominal value DKK 2 each:</font></td>
    <td align="right" width="6%"><font size="2" face="Times New Roman, Times, serif">53,743,600</font></td>
    <td align="right" width="49%">
      <div align="left"></div>
    </td>
  </tr>
  <tr>
    <td width="5%">&nbsp;</td>
    <td width="40%"><font size="2" face="Times New Roman, Times, serif">B shares,
      nominal value DKK 2 each:</font></td>
    <td align="right" width="6%"><font size="2" face="Times New Roman, Times, serif">263,503,331</font></td>
    <td align="right" width="49%">
      <div align="left"></div>
    </td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">Indicate by check mark
  if the registrant is a well-known seasoned issuer, as defined in Rule 405 of
  the Securities Act.</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="43%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">Yes&nbsp;&nbsp;<font size="2" face="Wingdings">&#253;</font></font></div>
    </td>
    <td width="19%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">&nbsp;No&nbsp;&nbsp;<font size="2" face="Wingdings">o</font></font></div>
    </td>
    <td width="38%">&nbsp;</td>
  </tr>
</table>
<p><font size="2" face="Times New Roman, Times, serif">Indicate by check mark
  whether the Registrant (1) has filed all reports required to be filed by Section
  13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
  (or for such shorter period that the Registrant was required to file such reports),
  and (2) has been subject to such filing requirements for the past 90 days,</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="43%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">Yes&nbsp;&nbsp;<font size="2" face="Wingdings">&#253;</font></font></div>
    </td>
    <td width="19%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">&nbsp;No&nbsp;&nbsp;<font size="2" face="Wingdings">o</font></font></div>
    </td>
    <td width="38%">&nbsp;</td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">Indicate by check mark
  whether the registrant is a large accelerated filer, an accelerated filer, or
  a non-accelerated filer. See definition of &#147;accelerated filer and large
  accelerated filer&#148; in Rule 12b-2 of the Exchange Act. (Check one):</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td>
      <div align="center"></div>
    </td>
    <td width="15%">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">Large
        accelerated filer&nbsp;&nbsp;<font size="2" face="Wingdings">&#253;</font></font></div>
    </td>
    <td width="15%">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">Accelerated
        filer &nbsp;&nbsp;<font size="2" face="Wingdings">o</font></font></div>
    </td>
    <td width="15%">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">&nbsp;Non-accelerated
        filer &nbsp;&nbsp;<font size="2" face="Wingdings">o</font></font></div>
    </td>
    <td>
      <div align="center"></div>
    </td>
  </tr>
</table>
<p><font size="2" face="Times New Roman, Times, serif">Indicate by check mark
  which financial statement item the Registrant has elected to follow:</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="43%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">Item
        17&nbsp;&nbsp;<font size="2" face="Wingdings">&#253;</font></font></div>
    </td>
    <td width="19%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">Item
        18&nbsp;&nbsp;<font size="2" face="Wingdings">o</font></font></div>
    </td>
    <td width="38%">&nbsp;</td>
  </tr>
</table>
<p><font size="2" face="Times New Roman, Times, serif">If this is an annual report,
  indicate by check mark whether the registrant is a shell company (as defined
  in Rule 12b-2 of the Exchange Act).</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="43%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">Yes&nbsp;&nbsp;<font size="2" face="Wingdings">o</font></font></div>
    </td>
    <td width="19%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">No&nbsp;&nbsp;<font size="2" face="Wingdings">&#253;</font></font></div>
    </td>
    <td width="38%">&nbsp;</td>
  </tr>
</table>
<hr size="1" width="100" noshade align="left">
<font face="Times New Roman, Times, serif" size="2"><sup><font size="1">1</font></sup><font size="1">
The outstanding number of shares represents the total number of shares less the
Company&#146;s holding of treasury shares.</font></font> <br>
<br>
<br>
<hr size=3 color=GRAY noshade>
<p align="center"></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<p><font face="Times New Roman, Times, serif" size="2"><a name="#contents"></a></font></p>
<p>&nbsp; </p>
<p><font size="2" face="Times New Roman, Times, serif">CONTENTS </font></p>
<table width="101%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td>&nbsp;</td>
    <td align="center" width="80%">&nbsp;</td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>Page</b></font></div>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td colspan=2><a href="#p3a"><font size="2" face="Times New Roman, Times, serif">INTRODUCTION</font></a></td>
    <td align="right"><a href="#p3a"><font size="2" face="Times New Roman, Times, serif">3</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><a href="#p3b"><font size="2" face="Times New Roman, Times, serif">ITEM
      1</font></a></td>
    <td><a href="#p3b"><font size="2" face="Times New Roman, Times, serif">IDENTITY
      OF DIRECTORS, EXECUTIVE MANAGEMENT AND ADVISORS</font></a></td>
    <td align="right"><a href="#p3b"><font size="2" face="Times New Roman, Times, serif">3</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p3c"><font size="2" face="Times New Roman, Times, serif">ITEM
      2</font></a></td>
    <td><a href="#p3c"><font size="2" face="Times New Roman, Times, serif">OFFER
      STATISTICS AND EXPECTED TIMETABLE</font></a></td>
    <td align="right"><a href="#p3c"><font size="2" face="Times New Roman, Times, serif">3</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><a href="#p3d"><font size="2" face="Times New Roman, Times, serif">ITEM
      3</font></a></td>
    <td><a href="#p3d"><font size="2" face="Times New Roman, Times, serif">KEY
      INFORMATION</font></a></td>
    <td align="right"><a href="#p3d"><font size="2" face="Times New Roman, Times, serif">3</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p5"><font size="2" face="Times New Roman, Times, serif">ITEM
      4</font></a></td>
    <td><a href="#p5"><font size="2" face="Times New Roman, Times, serif">INFORMATION
      ON THE COMPANY</font></a></td>
    <td align="right"><a href="#p5"><font size="2" face="Times New Roman, Times, serif">5</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p10"><font size="2" face="Times New Roman, Times, serif">ITEM
      5</font></a></td>
    <td><a href="#p10"><font size="2" face="Times New Roman, Times, serif">OPERATING
      AND FINANCIAL REVIEW AND PROSPECTS</font></a></td>
    <td align="right"><a href="#p10"><font size="2" face="Times New Roman, Times, serif">10</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><a href="#p16"><font size="2" face="Times New Roman, Times, serif">ITEM
      6</font></a></td>
    <td><a href="#p16"><font size="2" face="Times New Roman, Times, serif">DIRECTORS,
      SENIOR MANAGEMENT AND EMPLOYEES</font></a></td>
    <td align="right"><a href="#p16"><font size="2" face="Times New Roman, Times, serif">16</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p18"><font size="2" face="Times New Roman, Times, serif">ITEM
      7</font></a></td>
    <td><a href="#p18"><font size="2" face="Times New Roman, Times, serif">MAJOR
      SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</font></a></td>
    <td align="right"><a href="#p18"><font size="2" face="Times New Roman, Times, serif">18</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><a href="#p20"><font size="2" face="Times New Roman, Times, serif">ITEM
      8</font></a></td>
    <td><a href="#p20"><font size="2" face="Times New Roman, Times, serif">FINANCIAL
      INFORMATION</font></a></td>
    <td align="right"><a href="#p20"><font size="2" face="Times New Roman, Times, serif">20</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p21"><font size="2" face="Times New Roman, Times, serif">ITEM
      9</font></a></td>
    <td><a href="#p21"><font size="2" face="Times New Roman, Times, serif">THE
      OFFER AND LISTING</font></a></td>
    <td align="right"><a href="#p21"><font size="2" face="Times New Roman, Times, serif">21</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><a href="#p22"><font size="2" face="Times New Roman, Times, serif">ITEM
      10</font></a></td>
    <td><a href="#p22"><font size="2" face="Times New Roman, Times, serif">ADDITIONAL
      INFORMATION</font></a></td>
    <td align="right"><a href="#p22"><font size="2" face="Times New Roman, Times, serif">22</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p24"><font size="2" face="Times New Roman, Times, serif">ITEM
      11</font></a></td>
    <td><a href="#p24"><font size="2" face="Times New Roman, Times, serif">QUALITATIVE
      AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISKS</font></a></td>
    <td align="right"><a href="#p24"><font size="2" face="Times New Roman, Times, serif">24</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><a href="#p26a"><font size="2" face="Times New Roman, Times, serif">ITEM
      12</font></a></td>
    <td><a href="#p26a"><font size="2" face="Times New Roman, Times, serif">DESCRIPTION
      OF SECURITIES OTHER THAN EQUITY SECURITIES</font></a></td>
    <td align="right"><a href="#p26a"><font size="2" face="Times New Roman, Times, serif">26</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p26b"><font size="2" face="Times New Roman, Times, serif">ITEM
      13</font></a></td>
    <td><a href="#p26b"><font size="2" face="Times New Roman, Times, serif">DEFAULTS,
      DIVIDEND ARREARAGES AND DELINQUENCIES</font></a></td>
    <td align="right"><a href="#p26b"><font size="2" face="Times New Roman, Times, serif">26</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><a href="#p26c"><font size="2" face="Times New Roman, Times, serif">ITEM
      14</font></a></td>
    <td><a href="#p26c"><font size="2" face="Times New Roman, Times, serif">MATERIAL
      MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</font></a></td>
    <td>
      <div align="right"><a href="#p26c"><font size="2" face="Times New Roman, Times, serif">26</font></a></div>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p26d"><font size="2" face="Times New Roman, Times, serif">ITEM
      15</font></a></td>
    <td><a href="#p26d"><font size="2" face="Times New Roman, Times, serif">CONTROLS
      AND PROCEDURES</font></a></td>
    <td align="right"><a href="#p26d"><font size="2" face="Times New Roman, Times, serif">26</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><a href="#p27"><font size="2" face="Times New Roman, Times, serif">ITEM
      16A</font></a></td>
    <td><a href="#p27"><font size="2" face="Times New Roman, Times, serif">AUDIT
      COMMITTEE FINANCIAL EXPERT</font></a></td>
    <td align="right"><a href="#p27"><font size="2" face="Times New Roman, Times, serif">27</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p28a"><font size="2" face="Times New Roman, Times, serif">ITEM
      16B</font></a></td>
    <td><a href="#p28a"><font size="2" face="Times New Roman, Times, serif">CODE
      OF ETHICS</font></a></td>
    <td align="right"><a href="#p28a"><font size="2" face="Times New Roman, Times, serif">28</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><a href="#p28b"><font size="2" face="Times New Roman, Times, serif">ITEM
      16C</font></a></td>
    <td><a href="#p28b"><font size="2" face="Times New Roman, Times, serif">PRINCIPAL
      ACCOUNTANT FEES AND SERVICES</font></a></td>
    <td align="right"><a href="#p28b"><font size="2" face="Times New Roman, Times, serif">28</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p29a"><font size="2" face="Times New Roman, Times, serif">ITEM
      16D</font></a></td>
    <td><a href="#p29a"><font size="2" face="Times New Roman, Times, serif">EXEMPTIONS
      FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</font></a></td>
    <td align="right"><a href="#p29a"><font size="2" face="Times New Roman, Times, serif">29</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><a href="#p29b"><font size="2" face="Times New Roman, Times, serif">ITEM
      16E</font></a></td>
    <td><a href="#p29b"><font size="2" face="Times New Roman, Times, serif">PURCHASES
      OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</font></a></td>
    <td>
      <div align="right"><a href="#p29b"><font size="2" face="Times New Roman, Times, serif">29</font></a></div>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p29c"><font size="2" face="Times New Roman, Times, serif">ITEM
      17</font></a></td>
    <td><a href="#p29c"><font size="2" face="Times New Roman, Times, serif">FINANCIAL
      STATEMENTS</font></a></td>
    <td align="right"><a href="#p29c"><font size="2" face="Times New Roman, Times, serif">29</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><a href="#p32"><font size="2" face="Times New Roman, Times, serif">ITEM
      18</font></a></td>
    <td><a href="#p32"><font size="2" face="Times New Roman, Times, serif">FINANCIAL
      STATEMENTS</font></a></td>
    <td align="right"><a href="#p32"><font size="2" face="Times New Roman, Times, serif">32</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr bgcolor="#CCCCCC">
    <td><a href="#p33"><font size="2" face="Times New Roman, Times, serif">ITEM
      19</font></a></td>
    <td><a href="#p33"><font size="2" face="Times New Roman, Times, serif">EXHIBITS</font></a></td>
    <td align="right"><a href="#p33"><font size="2" face="Times New Roman, Times, serif">33</font></a></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td colspan=2><a href="#p37"><font size="2" face="Times New Roman, Times, serif">SIGNATURES</font></a></td>
    <td align="right"><a href="#p37"><font size="2" face="Times New Roman, Times, serif">37</font></a></td>
    <td>&nbsp;</td>
  </tr>
</table>
<p>&nbsp;</p><hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p3a"></a>INTRODUCTION
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In this Form 20-F, the
  terms &#145;the Company&#146;, &#145;Novo Nordisk&#146; and &#145;the Group&#146;
  refer to the parent company Novo Nordisk A/S together with its consolidated
  subsidiaries. The term &#145;Novo Nordisk A/S&#146; is used when addressing
  issues specifically related to this legal entity. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Throughout this Form 20-F
  the Company incorporates information on the various items by reference to its
  <i>Annual Report 2006</i> and <i>Annual Report 2005</i>. Therefore the information
  in this Form 20-F should be read in conjunction with our <i>Annual Report 2006</i>
  and <i>Annual Report 2005</i>, which were filed on Form 6-K on 9 February 2007
  and on 6 February 2006, respectively.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The Company publishes
  its financial statements in Danish kroner (DKK).</font></p>
<p align="center"> <font face="Times New Roman, Times, serif" size="2"><b><font size="3">PART
  I </font></b> </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p3b"></a>ITEM
  1 &nbsp;&nbsp;&nbsp;IDENTITY OF DIRECTORS, EXECUTIVE MANAGEMENT AND ADVISORS
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p3c"></a>ITEM
  2&nbsp;&nbsp;&nbsp; OFFER STATISTICS AND EXPECTED TIMETABLE </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p3d"></a>ITEM
  3&nbsp;&nbsp;&nbsp; KEY INFORMATION </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>SELECTED FINANCIAL
  DATA</u> </i></b> </font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2">US
        GAAP figures in DKK millions, except per share data</font></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2002</b></font></div>
    </td>
    <td align="center" width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2003</b></font></div>
    </td>
    <td align="center" width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2004</b></font></div>
    </td>
    <td align="center" width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2005</b></font></div>
    </td>
    <td align="center" width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2006</b></font></div>
    </td>
    <td align="center" width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp; </td>
    <td width="8%">
      <hr noshade size=1>
    </td>
    <td width="2%">&nbsp;</td>
    <td width="8%">
      <hr noshade size=1>
    </td>
    <td width="2%">&nbsp;</td>
    <td width="8%">
      <hr noshade size=1>
    </td>
    <td width="2%">&nbsp;</td>
    <td width="8%">
      <hr noshade size=1>
    </td>
    <td width="2%">&nbsp;</td>
    <td width="8%">
      <hr noshade size=1>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Net sales</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">24,866</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">26,158</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">29,031</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">33,760</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">38,743</font></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Operating profit from
      continuing operations</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">5,932</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">6,407</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">6,707</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">7,668</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">8,784</font></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Operating profit</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">5,932</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">6,407</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">6,707</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">7,668</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">8,784</font></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Net profit from continuing
      operations</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">4,270</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">4,844</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">4,685</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">4,898</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">6,310</font></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Net profit</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">4,270</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">4,844</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">4,685</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">4,898</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">6,310</font></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Earnings per share/ADR
      from continuingoperations</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">12.32</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">14.20</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">13.92</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">14.92</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">19.66</font></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Total assets</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">32,077</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">35,004</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">37,643</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">41,887</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">44,347</font></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Net assets</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">22,826</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">25,155</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">26,582</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">26,984</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">29,235</font></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Capital stock</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">709</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">709</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">709</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">709</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">674</font></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Treasury stock</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">(19</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">(33</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">(45</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">(61</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">(39</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">)</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Dividends per share/ADR</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">3.60</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">4.40</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">4.80</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">6.00</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">7.00</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif"> *)</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Dividends per share/ADR
      in USD</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">0.51</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">0.74</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">0.88</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">0.95</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">1.24</font></td>
    <td width="2%"><font size="2" face="Times New Roman, Times, serif">*)</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Diluted earnings per
      share/ADR</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">12.30</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">14.18</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">13.86</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">14,86</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">19.55</font></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Number of shares (million)</font></td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">354.7</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">354.7</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">354.7</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">354.7</font></td>
    <td width="2%">&nbsp;</td>
    <td align="right" width="8%"><font size="2" face="Times New Roman, Times, serif">337.0</font></td>
    <td width="2%">&nbsp;</td>
  </tr>
</table>
<p> <font size="1" face="Times New Roman, Times, serif">*) &nbsp;Proposed dividend
  per share. For USD translation the exchange rate at 31 December 2006 from Danmarks
  Nationalbank (The Central Bank of Denmark) is used (USD 1 = DKK 5.6614) </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Reference is made to &#145;Consolidated
  Financial Statement&#146;, page 54-104 in our <i>Annual Report</i> 2006 for
  further financial data. </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">3</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_4"></a> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Exchange rates </b>
  </font><br>
  <font size="2" face="Times New Roman, Times, serif">The following table sets
  forth, for the calendar periods indicated, certain information concerning Dan-marks
  Nationalbank&#146;s daily official exchange rates for US dollars (USD) in terms
  of Danish kroner expressed in DKK per USD 1.00. These rates closely approximate
  the noon buying rate for Danish kroner for cable transfers in New York City
  as announced by the Federal Reserve Bank of New York for customs purposes on
  the relevant dates.</font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td><font face="Times New Roman, Times, serif" size="2"><b>Month</b></font></td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>High</b></font></div>
    </td>
    <td width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>Low</b></font></div>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td width="8%">
      <hr noshade size=1>
    </td>
    <td width="2%">&nbsp;</td>
    <td width="8%">
      <hr noshade size=1>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">July 2006</font></td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.9774</font></div>
    </td>
    <td width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.8310</font></div>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">August 2006</font></td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.8663</font></div>
    </td>
    <td width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.7754</font></div>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">September 2006</font></td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.8964</font></div>
    </td>
    <td width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.8050</font></div>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">October 2006</font></td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.9573</font></div>
    </td>
    <td width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.8542</font></div>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">November 2006</font></td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.8706</font></div>
    </td>
    <td width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.6474</font></div>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">December 2006</font></td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.6920</font></div>
    </td>
    <td width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.5929</font></div>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">1-26 January 2007</font></td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.7806</font></div>
    </td>
    <td width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.6191</font></div>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
</table>
<table align="center" border=0 cellspacing=0 cellpadding=0 width="100%">
  <tr>
    <td>&nbsp;</td>
    <td width="2%">&nbsp;</td>
    <td align="center" width="8%">&nbsp;</td>
    <td width="2%">&nbsp;</td>
    <td align="center" width="8%">&nbsp;</td>
    <td width="2%">&nbsp;</td>
    <td align="center" width="8%">&nbsp;</td>
    <td width="2%">&nbsp;</td>
    <td align="center" width="8%">&nbsp;</td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font face="Times New Roman, Times, serif" size="2"><b>Year</b></font></td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>Average
        rate<sup>2</sup></b></font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>Period
        end rate</b></font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>High</b></font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>Low</b></font></div>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>
      <hr noshade size=1>
    </td>
    <td>&nbsp;</td>
    <td>
      <hr noshade size=1>
    </td>
    <td>&nbsp;</td>
    <td>
      <hr noshade size=1>
    </td>
    <td>&nbsp;</td>
    <td>
      <hr noshade size=1>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif">2002</font></div>
    </td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">7.8403</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">7.0822</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">8.6591</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">7.0822</font></div>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif">2003</font></div>
    </td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">6.5271</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.9576</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">7.1592</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.9554</font></div>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif">2004</font></div>
    </td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.9774</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.4676</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">6.3047</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.4580</font></div>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif">2005</font></div>
    </td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">6.0298</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">6.3241</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">6.3917</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.5061</font></div>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif">2006</font></div>
    </td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.9118</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.6614</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">6.3082</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5.5929</font></div>
    </td>
    <td>&nbsp;</td>
  </tr>
</table>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>CAPITALIZATION
  AND INDEBTEDNESS</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>REASONS FOR THE
  OFFER AND USE OF PROCEEDS</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>RISK FACTORS</u></i></b>
  </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Forward-looking Statement
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">The information set forth
  in this annual report on Form 20-F contains forward-looking statements as the
  term is defined in the US Private Securities Litigation Reform Act of 1995.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">This in particular relates
  to information included under the headings &#145;Off-Balance Sheet Arrangements&#146;
  and &#145;Tabular Disclosure of Contractual Obligations&#146; under Item 5 and
  in the Company&#146;s <i>Annual Report</i> <i>2006</i>, including under the
  headings &#145;Risk Management&#146;, &#145;Management report and discussion
  2006&#146; and note 32 &#145;Financial Risk&#146; with reference to plans, forecasts,
  expectations, strategies, projections and assessment of risks.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Words such as &#145;believe&#146;,
  &#145;expect&#146;, &#145;may&#146;, &#145;will&#146;, &#145;plan&#146;, &#145;strategy&#146;,
  &#145;prospect&#146;, &#145;foresee&#146;, &#145;estimate&#146;, &#145;project&#146;,
  &#145;anticipate&#146;, &#145;can&#146;, &#145;intend&#146; and similar words
  identify forward-looking statements. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Examples of such forward-looking
  statements include, but are not limited to: </font></p>
<table width="100%" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td valign="top" width="3%">&nbsp;</td>
    <td valign="top" width="3%"><font face="Times New Roman, Times, serif" size="2">&nbsp;&#149;</font></td>
    <td valign="top">&nbsp;</td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">statements
      of plans, objectives or goals for future operations including those related
      to Novo Nordisk&#146;s products, product research, product introductions
      and product approvals as well as co-operations in relation thereto</font></td>
  </tr>
</table>
<p>&nbsp; </p>
<hr size="1" width="100" noshade align="left">
<table width="100%" cellspacing="0" cellpadding="0">
  <tr>
    <td width="3%"><font face="Times New Roman, Times, serif" size="1"><sup>2&nbsp;&nbsp;&nbsp;
      </sup> </font></td>
    <td><font face="Times New Roman, Times, serif" size="1">The average exchange
      rate is calculated by using the exchange rate on the last day of each month
      according to Danmarks Nationalbank&#146;s daily official exchange rates.<sup>
      </sup></font></td>
  </tr>
</table>
<p><font face="Times New Roman, Times, serif" size="2"> </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">4</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<table width="100%" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td valign="top" width="3%"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;</font></td>
    <td valign="top" width="3%"><font face="Times New Roman, Times, serif" size="2">&nbsp;&#149;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">statements
      containing projections of revenues, income (or loss), earnings per share,
      capital expenditures, dividends, capital structure or other net financials</font></td>
  </tr>
  <tr>
    <td valign="top" width="3%"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;</font></td>
    <td valign="top" width="3%"><font face="Times New Roman, Times, serif" size="2">&nbsp;&#149;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">statements
      of future economic performance</font></td>
  </tr>
  <tr>
    <td valign="top" width="3%"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;</font></td>
    <td valign="top" width="3%"><font face="Times New Roman, Times, serif" size="2">&nbsp;&#149;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">statements
      of the assumptions underlying or relating to such statements.</font></td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">These statements are based
  on current plans, estimates and projections, and therefore undue reliance should
  not be placed on them. Moreover, such statements are not guarantees of future
  results. By their very nature, forward-looking statements involve inherent risks
  and uncertainties, both general and specific, and risks exist that the predictions,
  forecasts, projections and other forward-looking statements will not be achieved.
  Novo Nordisk cautions that a number of important factors could cause actual
  results to differ materially from the plans, objectives, expectations, estimates
  and intentions expressed in such forward-looking statements. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Factors that may affect
  future results include, but are not limited to, interest rate and currency exchange
  rate fluctuations, delay or failure of development projects, interruptions of
  supplies and production, product recall, pressure on insulin prices, unexpected
  contract breaches or terminations, government-mandated or market driven price
  decreases for Novo Nordisk&#146;s products, introduction of competing products,
  Novo Nordisk&#146;s ability to successfully market current and new products,
  exposure to product liability and legal proceedings and investigations, changes
  in reimbursement rules and governmental laws and related interpretation thereof,
  perceived or actual failure to adhere to ethical marketing practices, developments
  in international activities, which also involve certain political risks, investments
  in and divestitures of domestic and foreign companies and unexpected growth
  in costs and expenses.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Forward-looking statements
  speak only as of the date they were made and, unless required by law, Novo Nordisk
  is under no duty and undertakes no obligation to update or revise any of them
  , after the distribution of this annual report, whether as a result of new information,
  future events or otherwise. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p5"></a>ITEM
  4&nbsp;&nbsp;&nbsp; INFORMATION ON THE COMPANY </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>HISTORY AND DEVELOPMENT
  OF THE COMPANY</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk A/S was formed
  in 1989 by a merger of two Danish companies, Nordisk Gentofte A/S and Novo Industri
  A/S. Novo Industri A/S was the surviving company and its name was changed to
  Novo Nordisk A/S. The business activities of Nordisk Gentofte A/S were established
  in 1923 by August Krogh, H. C. Hagedorn and A. Kongsted, and the business activities
  of Novo Industri A/S were established in 1925 by Harald and Thorvald Pedersen.
  The business of both companies from the beginning was production and sale of
  insulin for the treatment of diabetes. After splitting-off its historical industrial
  enzyme business into the separate company, Novozymes A/S, in November 2000 Novo
  Nordisk today is a focused healthcare company.</font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Legal name:</font></td>
    <td width="73%"><font size="2" face="Times New Roman, Times, serif">Novo Nordisk
      A/S</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Commercial name:</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Novo Nordisk</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Domicile:</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Novo All&eacute; 1,
      DK-2880 Bagsv&aelig;rd, DENMARK</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Tel: +45 4444 8888</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Fax: +45 4449 0555</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Website: </font><font color="#0000ff" size="2" face="Times New Roman, Times, serif"><u>www.novonordisk.com</u></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <hr noshade size=1>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">(The contents of this
      website are not incorporated by reference into this Form 20-F.)</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Date of incorporation:</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">28 November 1931</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Legal form of the
      Company:</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">A Danish limited liability
      company</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Legislation under
      which</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">the Company operates:</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">Danish law</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Country of incorporation:</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">The Kingdom of Denmark</font></td>
  </tr>
</table>
<p>&nbsp;</p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">5</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_6"></a> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Important events in
  2006</b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Reference is made to &#145;Business
  results 2006&#146;, pages 6&#150;19 in our <i>Annual Report 2006</i> for a list
  of important events in 2006. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Capital expenditure
  in 2006, 2005 and 2004 </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">The total net capital expenditure
  for property, plant and equipment was DKK 2.8 billion in 2006 compared with
  DKK 3.7 billion in 2005 and DKK 3.0 billion in 2004. The lower level of capital
  expenditure in 2006, compared to the previous two years, was primarily related
  to lower overall investment needs and completion of a number of investments
  in Denmark, the US and Brazil.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Investments in 2006 were
  mainly capacity expansion within the diabetes care area, increasing the capacity
  for modern insulin (insulin analogues), insulin formulation and filling as well
  as insulin delivery devices and GLP-1 analogue. The investments are financed
  internally. No significant divestments took place in the period 2003-2006. No
  significant investments or divestments have taken place in 2007 to date.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk expects to
  invest around DKK 3 billion in fixed assets in 2007. Significant investments
  are expected in Denmark, the United States, China and Brazil. The expected level
  of investment in 2007 is primarily related to the construction of additional
  assembly capacity for disposable devices, as well as construction of launch
  capacity for new products. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Public takeover offers
  in respect to the Company&#146;s shares </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">No such offers have occurred
  during 2006 or 2007 to date. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>BUSINESS OVERVIEW</u>
  </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk is a healthcare
  company and a world leader in diabetes care. The company has one of the broadest
  diabetes product portfolios in the industry, including some of the most advanced
  products in the area of insulin delivery systems. In addition, Novo Nordisk
  has a leading position in areas such as haemostasis management, growth hormone
  therapy and hormone replacement therapy. Novo Nord-isk manufactures and markets
  pharmaceutical products and services that make a significant difference to patients,
  the medical profession and society. Headquartered in Denmark, Novo Nordisk employs
  approximately 23,000 full-time equivalent employees in approximately 80 countries,
  and markets its products in approximately 180 countries. </font></p>
<p>&nbsp; </p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">6</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_7"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif"><b>Segment information
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Novo Nordisk is engaged
  in the discovery, development, manufacturing and marketing of pharmaceutical
  products and has two business segments &#150; diabetes care and biopharmaceuticals.
  The diabetes </font><font size="2" face="Times New Roman, Times, serif">care
  segment covers Novo Nordisk&#146;s insulin franchise, including insulin analogues,
  human insulin and insulin-related sales and OADs (oral antidiabetic drugs).
  The biopharmaceuticals segment covers the therapy areas: haemostasis management
  (NovoSeven<sup>&reg;</sup>), growth hormone therapy, hormone replacement therapy
  and other products.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">For information on sales
  by business segment and geographic segment, reference is made to <i>Annual Report
  2006</i> Note 4 &#145;Segment information&#146;. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Seasonality </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Sales of individual products
  in individual markets may be subject to seasonality and fluctuations from quarter
  to quarter, but besides a general trend of increasing sales per quarter between
  the first quarter to fourth quarter, the Company&#146;s consolidated results
  of operations have not been subject to significant seasonality. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Raw materials </b>
  </font><br>
  <font size="2" face="Times New Roman, Times, serif">As a focused healthcare
  company the impact on the overall profitability of Novo Nordisk from variations
  in raw material prices is unlikely to be significant. No raw material supply
  shortage has had a significant impact on the Company&#146;s ability to supply
  the market. The Company&#146;s production is largely based on common and readily
  available raw materials with relatively low price volatility. Certain specific
  raw materials are, however, less available. For these raw materials, it is the
  policy of Novo Nordisk to develop close and long-term relationships with key
  suppliers as well as to secure dual sourcing whenever possible and when relevant
  maintain a minimum safety level of raw material inventories. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Marketing and competition
  </b></font><br>
  <font size="2" face="Times New Roman, Times, serif">Novo Nordisk&#146;s insulin
  and other pharmaceutical products are marketed and distributed through subsidiaries,
  distributors and independent agents with responsibility for specific geographical
  areas. The most important markets are the United States, Japan and the major
  European countries. Key emerging markets, such as China, Russia, India and Turkey,
  are increasingly adding to growth. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Market conditions within
  the pharmaceutical industry continue to change, including efforts by both private
  and governmental entities to reduce/control costs in specific therapeutic areas.
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Historically, the market
  for insulin has been more sensitive to quality of products and services than
  to price. Most of the countries, in which the Company sells insulin, subsidize
  or control pricing. In most markets insulin is a prescription drug. In the United
  States, however human insulin may be sold over the counter whereas modern insulin
  (insulin analogues) requires a prescription. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In the normal course of
  its business the Company enters into numerous contracts with customers, suppliers,
  agents and industry partners. Some of the most important contracts include:
  in- and out-licensing (patent rights, products and development projects), co-promotion
  and co-development agreements, large tender orders and long-term sub-supplier
  agreements. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">New manufacturing processes,
  efficient quality systems and innovative research and development are all important
  competitive factors affecting the Company. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Several of the major international
  pharmaceutical companies have entered the diabetes market, specifically in the
  area of oral products for treatment of type 2 diabetes. The insulin market has
  few producers and Novo Nordisk, Eli Lilly and Sanofi-Aventis are the only three
  global companies. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Patents </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Patents are important intellectual
  property rights of Novo Nordisk. Novo Nordisk endeavors to secure the strongest
  possible protection for those inventions, which will maintain and expand the
  competitiveness of Novo Nordisk in accordance with the Company&#146;s Vision,
  Business Strategies, Patent Policy and the competitive environment. </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">7</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_8"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">The Company anticipates
  that the expiration of certain patents could have impact on the sales of the
  Company within the next five years. However, with the continuing transition
  from human insulin to modern insulin (insulin analogues), an increasing proportion
  of Novo Nordisk&#146;s sales in the major markets is protected by patents for
  modern insulin (insulin analogues) expiring in 2011 and beyond. Furthermore,
  with the exception of Japan, where the NovoSeven<sup>&reg;</sup> patent is scheduled
  to expire in 2008, NovoSeven<sup>&reg;</sup> sales are protected by patents
  which expire in 2010 and 2011. Activ-elle<sup>&reg;</sup>/Activella<sup>&reg;</sup>
  sales may become exposed to generic competition in the US in 2007 and expiration
  of the Supplementary Protection Certificates in Europe in 2009. Sales of Prandin<sup>&reg;</sup>/NovoNorm<sup>&reg;</sup>
  an oral antidiabetic drug, may become exposed to generic competition because
  the patent expires from 2009 in the United States and Europe. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Like other companies engaged
  in production based upon rDNA technology, Novo Nordisk has obtained licenses
  under various patents which entitle the Company to use processes and methods
  of manufacturing covered by such patents. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Impact of regulations
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">As a pharmaceutical company,
  Novo Nordisk depends on government approvals relating to the production, development,
  marketing and reimbursement of its products. Important regulatory bodies include
  the United States Food and Drug Administration and the European Medicines Agency.
  Treatment guidelines from non-governmental organizations like the European Association
  for the Study of Diabetes and the American Diabetes Association may also have
  an impact on the Company.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>ORGANIZATIONAL
  STRUCTURE</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">For information regarding
  the organizational structure and securities exchange listings of Novo Nord-isk
  A/S, reference is made to the sections &#145;Corporate governance&#146; on pages
  108-109 and &#146;Shareholder information&#146; on pages 115-116 in our <i>Annual
  Report 2006</i>.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Reference is made to the
  section &#145;Shareholder information&#146; on pages 115-116 in our <i>Annual
  Report 2006 </i>regarding the parent (Novo A/S) and ultimate parent of Novo
  Nordisk (Novo Nordisk Foundation) and their share ownership in Novo Nordisk
  A/S.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Information about the
  companies in the Novo Nordisk Group, set forth in the Company&#146;s <i>Annual
  Report 2006</i> on pages 100-101, &#145;Companies in the Novo Nordisk Group&#146;,
  is incorporated herein by reference. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>PROPERTY, PLANT
  AND EQUIPMENT</u> </i></b> </font></p>
<p><font size="2" face="Times New Roman, Times, serif">The Company is headquartered
  in Bagsv&aelig;rd, Denmark where the Company occupies several office buildings.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The Company&#146;s major
  research and development facilities are located at a number of sites in Denmark.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The major production facilities
  owned by the Company are located at a number of sites in Denmark, and the international
  production or processing facilities are located in the United States, France,
  Japan, China and Brazil.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The Company believes that
  its current production facilities including facilities under construction are
  sufficient to meet its capacity requirements. Please refer to the sections &#145;Capital
  expenditure in 2006, 2005 and 2004&#146; under Item 4 for more information about
  the current expansion programs. For the nature of the Company&#146;s property,
  plant and equipment as of 31 December 2005 and 2006 see Note 15 in our Annual
  Report<i> 2006</i>. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Reference is made to Note
  4 in our <i>Annual Report 2006</i> regarding the location of the property, plant
  and equipment as of 31 December 2005 and 2006. </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">8</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_9"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">Property, plant and equipment
  include several production sites worldwide at the end of 2006. There are no
  material encumbrances on the properties. Active pharmaceutical ingredient production
  is mainly located in Denmark, primarily in Kalundborg and secondarily in Hiller&oslash;d,
  Bagsv&aelig;rd and Gentofte. Below is a tabular presentation of the production
  sites. </font></p>
<table width="100%" align="center" border=1 cellspacing=0 cellpadding=0>
  <tr valign="bottom">
    <td><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Major
      production facilities</b></font></td>
    <td align="center" width="14%"><font face="Times New Roman, Times, serif" size="2"><b>Size
      of site,<br>
      square meters</b></font></td>
    <td align="center" width="55%"><font face="Times New Roman, Times, serif" size="2"><b>Major
      activities</b></font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Kalundborg,
      Denmark<br>
      </font><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.
      Diabetes,</font><font face="Times New Roman, Times, serif" size="2"><br>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Factor VII Production</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">138,000&nbsp;&nbsp;</font></div>
      <div align="right">&nbsp;</div>
      <div align="right">&nbsp;</div>
    </td>
    <td valign="bottom">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"> &nbsp;&nbsp;Active
        pharmaceutical ingredients for diabetes<br>
        &nbsp;&nbsp;Active pharmaceutical ingredients for haemo&nbsp;stasis management
        </font></div>
      <div align="left"></div>
      <div align="left"></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Hiller&oslash;d,
      Denmark</font><font face="Times New Roman, Times, serif" size="2"><br>
      <br>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Devices Manufacturing and Sourcing<br>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Diabetes <br>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Factor VII Production </font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">86,000&nbsp;&nbsp;</font></div>
      <div align="right">&nbsp;</div>
      <div align="right">&nbsp;</div>
      <div align="right">&nbsp;</div>
    </td>
    <td>
      <div align="left">&nbsp;</div>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Durable
        devices and components for disposable devices<br>
        &nbsp;&nbsp;Products for diabetes. <br>
        <br>
        &nbsp;&nbsp;Active pharmaceutical ingredients for haemostasis management.
        </font></div>
      <div align="left"></div>
      <div align="left"></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Montes
      Claros, Brazil,</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">59,000&nbsp;&nbsp;</font></div>
    </td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Products
        for diabetes</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Gentofte,
      Denmark</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">44,000&nbsp;&nbsp;</font></div>
    </td>
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Products
        for growth hormone therapy, gluca&nbsp;&nbsp;pharmaceutical ingredients
        for diabetes.</font></div>
    </td>
  </tr>
  <tr valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;M&aring;l&oslash;v,
      Denmark</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">36,000&nbsp;&nbsp;</font></div>
    </td>
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Hormone
        replacement therapy products<br>
        &nbsp;&nbsp;Products for Oral Anti Diabetes treatment </font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Chartres,
      France</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">33,000&nbsp;&nbsp;</font></div>
    </td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Products
        for diabetes</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Bagsv&aelig;rd,
      Denmark</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">26,000&nbsp;&nbsp;</font></div>
    </td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Products
        for diabetes</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Clayton,
      North Carolina, U.S., expansion in progress</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">24,000&nbsp;&nbsp;</font></div>
    </td>
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Products
        for diabetes</font></div>
    </td>
  </tr>
  <tr valign="top">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Tianjin,
      China</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">12,000&nbsp;&nbsp;</font></div>
    </td>
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Products
        for diabetes.<br>
        &nbsp;&nbsp;Durable devices. </font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Hj&oslash;rring,
      Denmark</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">11,000&nbsp;&nbsp;</font></div>
    </td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Production
        of needles</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Koriyama,
      Japan</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">8,000&nbsp;&nbsp;</font></div>
    </td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Packaging
        of products for the Japanese market</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;V&aelig;rl&oslash;se,
      Denmark</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">6,000&nbsp;&nbsp;</font></div>
    </td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Products
        for diabetes</font></div>
    </td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">Facilities for purification
  of insulin Detemir is now fully ramped up to its nominal capacity. This ensures
  adequate capacity to complete the global rollout and to meet the growing demand
  for Levemir<sup>&reg;</sup>. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The expansion of the Aspart
  capacity initiated in 2005 has also been completed. This ensures adequate capacity
  to meet the growing demand in the future for the NovoRapid<sup>&reg;</sup>/NovoLog<sup>&reg;</sup>
  and the No-voMix<sup>&reg;</sup>/NovoLogMix<sup>&reg;</sup> products. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Furthermore, an investment
  is ongoing to establish capacity for a once-daily GLP-1 analogue. Construction
  is completed and the facility is expected to be approved in 2009. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">An expansion project in
  Montes Claros, Brazil, has been completed and final validation is ongoing. The
  main objective of the project is to establish additional Penfill<sup>&reg;</sup>
  filling capacity. At the end of 2006, Novo Nordisk initiated a project to establish
  FlexPen<sup>&reg;</sup> assembly and packaging capacity in Montes Claros. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In 2006, Novo Nordisk
  Board of Directors approved an investment into an insulin strip launch plant.
  The strips are intended to be used in connection with the AERx<sup>&reg;</sup>
  iDMS pulmonary drug delivery system. The facility is located in Hayward, California
  and is part of Novo Nordisk Delivery Technologies, Inc. </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">9</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_10"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk completed
  its expansion project in Tianjin, China and the plant will assemble durable
  devices and will supply both the domestic Chinese market and export markets.
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Major production sites
  worldwide are certified according to the international standard ISO 14001 (Environmental
  Management Standard), except for the site in Montes Claros, Brazil which is
  expected to be certified in 2007. The goal is to pursue control of significant
  environmental impacts of the Company&#146;s operations worldwide. In 2005, a
  corporate CO<sub>2</sub> strategy covering the years 2005-2014 was developed
  with the aim to reduce CO<sub>2</sub> emissions globally. By 2014, Novo Nordisk
  plans to reduce its CO<sub>2</sub> emissions by 10% compared to 2004 emission
  levels. This is an ambitious target for the com</font><font size="2" face="Times New Roman, Times, serif">pany&#146;s
  climate strategy, considering that Novo Nordisk emissions would increase by
  an estimated 60-70% in the absence of emission reduction programmes. The target
  has been defined in an agreement with the World Wide Fund for Nature (WWF),
  which makes Novo Nordisk the 10<sup>th</sup> company in the world to become
  a member of the Climate Savers Programme.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>UNRESOLVED STAFF
  COMMENTS</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">None.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p10"></a>ITEM
  5 &nbsp;&nbsp;&nbsp;OPERATING AND FINANCIAL REVIEW AND PROSPECTS </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>CRITICAL ACCOUNTING
  ESTIMATES</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Reference is made to Note
  1 Summary of significant accounting policies and Note 3 regarding Critical accounting
  estimates and judgements in our <i>Annual Report 2006</i>. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>NEW ACCOUNTING
  PRONOUNCEMENTS</u> </i></b> </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>New US accounting pronouncements
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">New US accounting pronouncements
  generally only have implications for the US GAAP reconciliation of IFRS figures
  to US GAAP figures.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In February 2006, the
  FASB issued SFAS 155, Accounting for Certain Hybrid Financial Instruments -
  an amendment of FASB Statements No. 133 and 140. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">This Statement amends
  FASB Statements No. 133, Accounting for Derivative Instruments and Hedging Activities,
  and No. 140, Accounting for Transfers and Servicing of Financial Assets and
  Extinguishments of Liabilities. This Statement resolves issues addressed in
  Statement 133 Implementation Issue No. D1, &#147;Application of Statement 133
  to Beneficial Interests in Securitized Financial Assets.&#148; Management does
  not believe that SFAS 155 will have a material effect on the Company&#146;s
  financial statement when it is adopted in 2007.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In March 2006, the FASB
  issued SFAS 156, Accounting for Servicing of Financial Assets - an amendment
  of FASB Statement No. 140.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">This Statement amends
  FASB Statement No. 140, Accounting for Transfers and Servicing of Financial
  Assets and Extinguishments of Liabilities, with respect to the accounting for
  separately recognized servicing assets and servicing liabilities.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Management does not believe
  that SFAS 156 will have a material effect on the Company&#146;s financial statement
  when it is adopted in 2007.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In June 2006, the FASB
  issued FIN 48, Accounting for Uncertainty in Income Taxes&#151;an interpretation
  of FASB Statement No. 109. </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">10</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_11"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">This Interpretation clarifies
  the accounting for uncertainty in income taxes recognized in an enter</font><font size="2" face="Times New Roman, Times, serif">prise&#146;s
  financial statements in accordance with FASB Statement No. 109, Accounting for
  Income Taxes. This Interpretation prescribes a recognition threshold and measurement
  attribute for the financial statement recognition and measurement of a tax position
  taken or expected to be taken in a tax return. This Interpretation also provides
  guidance on derecognition, classification, interest and penalties, accounting
  in interim periods, disclosure, and transition. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The evaluation of a tax
  position in accordance with this Interpretation is a two-step process. The first
  step is recognition: The enterprise determines whether it is more likely than
  not that a tax position will be sustained upon examination, including resolution
  of any related appeals or litigation processes, based on the technical merits
  of the position. In evaluating whether a tax position has met the more-likely-than-not
  recognition threshold, the enterprise should presume that the position will
  be examined by the appropriate taxing authority that would have full knowledge
  of all relevant information. The second step is measurement: A tax position
  that meets the more-likely-than-not recognition threshold is measured to determine
  the amount of benefit to recognize in the financial statements. The tax position
  is measured at the largest amount of benefit that is greater than 50 percent
  likely of being realized upon ultimate settlement. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Management does not believe
  that FIN 48 will have a material effect on the Company&#146;s financial statement
  when it is adopted in 2007.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In September 2006, the
  FASB issued SFAS 157, Fair Value Measurements. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">This Statement defines
  fair value, establishes a framework for measuring fair value in generally accepted
  accounting principles (GAAP), and expands disclosures about fair value measurements.
  This Statement applies under other accounting pronouncements that require or
  permit fair value measurements, the Board having previously concluded in those
  accounting pronouncements that fair value is the relevant measurement attribute.
  Accordingly, this Statement does not require any new fair value measurements.
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Management does not believe
  that SFAS 157 will have a material effect on the Company&#146;s financial statement
  when it is adopted in 2008.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In September 2006, the
  FASB issued SFAS 158, Employers&#146; Accounting for Defined Benefit Pension
  and Other Postretirement Plans&#151;an amendment of FASB Statements No. 87,
  88, 106, and 132(R). This Statement requires an employer that is a business
  entity and sponsors one or more single-employer defined benefit plans to: </font></p>
<table width="100%" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td valign="top" width="3%">&nbsp;</td>
    <td valign="top" width="3%"><font size="2" face="Times New Roman, Times, serif">a.&nbsp;&nbsp;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">Recognize
      the funded status of a benefit plan&#151;measured as the difference between
      plan assets at fair value (with limited exceptions) and the benefit obligation&#151;in
      its statement of financial position. For a pension plan, the benefit obligation
      is the projected benefit obligation; for any other postretirement benefit
      plan, such as a retiree health care plan, the benefit obligation is the
      accumulated postretirement benefit obligation.</font></td>
  </tr>
  <tr>
    <td valign="top" width="3%">&nbsp;</td>
    <td valign="top" width="3%"><font size="2" face="Times New Roman, Times, serif">b.&nbsp;&nbsp;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">Recognize
      as a component of other comprehensive income, net of tax, the gains or losses
      and prior service costs or credits that arise during the period but are
      not recognized as components of net periodic benefit cost pursuant to FASB
      Statement No. 87, Employers&#146; Accounting for Pensions, or No. 106, Employers&#146;
      Accounting for Postretirement Benefits Other Than Pensions. Amounts recognized
      in accumulated other comprehensive income, including the gains or losses,
      prior service costs or credits, and the transition asset or obligation remaining
      from the initial application of Statements 87 and 106, are adjusted as they
      are subsequently recognized as components of net periodic benefit cost pursuant
      to the recognition and amortization provisions of those Statements.</font></td>
  </tr>
  <tr>
    <td valign="top" width="3%">&nbsp;</td>
    <td valign="top" width="3%"><font size="2" face="Times New Roman, Times, serif">c.&nbsp;&nbsp;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">Measure
      defined benefit plan assets and obligations as of the date of the employer&#146;s
      fiscal year-end statement of financial position (with limited exceptions).</font></td>
  </tr>
</table>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">11</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_12"></a> </font>
<table width="100%" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td valign="top" width="3%">&nbsp;</td>
    <td valign="top" width="3%"><font size="2" face="Times New Roman, Times, serif">d.&nbsp;&nbsp;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">Disclose
      in the notes to financial statements additional information about certain
      effects on net periodic benefit cost for the next fiscal year that arise
      from delayed recognition of the gains or losses, prior service costs or
      credits, and transition asset or obligation.</font></td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">Upon initial application
  of this Statement and subsequently, an employer should continue to apply the
  provisions in Statements 87, 88, and 106 in measuring plan assets and benefit
  obligations as of the date of its statement of financial position and in determining
  the amount of net periodic benefit cost. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">SFAS 158 has been adopted
  in 2006 and effects the US GAAP reconciliation of IFRS figures to US GAAP figures.
  Reference is made to Note 38 in our <i>Annual Report</i> <i>2006</i> regarding
  the impact.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>OPERATING RESULTS</u>
  </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The following discussion
  includes certain forward-looking statements. Such forward-looking statements
  are subject to a number of risk factors, including material risks, uncertainties
  and contingencies which could cause actual results to differ materially from
  the forward-looking statements. For a discussion of important factors that could
  cause actual results to differ materially from the forward-looking statements,
  see the discussion under the caption &#145;Risk factors&#146; contained under
  Item 3. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The condition and development
  in the financial conditions of the Group are described in our <i>Annual Report
  2006</i> and our <i>Annual Report 2005</i>. The information in this section
  is based on these reports and should be read in conjunction with our annual
  reports. The analysis and discussions included in our annual reports are primarily
  based on the financial statements which, from 1 January 2004 are prepared in
  accordance with International Financial Reporting Standards.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>2006 compared with
  2005</b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">The following portions of
  our <i>Annual Report 2006</i> constitute the Board of Directors and Executive
  Management&#146;s discussion and analysis of results of operations (incorporated
  herein by reference):</font></p>
<p> <font size="2" face="Times New Roman, Times, serif"> &#145;Management report
  and discussion&#146; (pages 8-15) </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">On a US GAAP basis, net
  profit in 2006 increased by 29% compared to 2005. The net profit in accordance
  with US GAAP was 2% lower than the net profit under IFRS, mainly due to differences
  in the treatment of accounting for acquired in-process research and development
  projects and aquired single-purpose R&amp;D assets.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Please refer to Note 38
  in our <i>Annual Report 2006</i> for further information on the reconciliation
  of net profit to US GAAP for the years 2004 to 2006. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>2005 compared with
  2004</b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">The following portions of
  our <i>Annual Report 2005</i> constitute the Board of Directors and Executive
  Management&#146;s discussion and analysis of results of operations (incorporated
  herein by reference):</font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif"> &#145;Management
  report and discussion&#146; (pages 42-53) </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">12</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_13"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">On a US GAAP basis, net
  profit in 2005 increased by 5% compared to 2004. The net profit in accordance
  with US GAAP was 16.5% lower than the net profit under IFRS, mainly due to differences
  in the treatment of accounting for acquired in-process research and development
  projects and investments in research and development companies.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Please refer to Note 38
  in our <i>Annual Report 2005</i> for further information on the reconciliation
  of net profit to US GAAP for the years 2003 to 2005. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif"><b>Segment information<br>
  </b></font><font size="2" face="Times New Roman, Times, serif">The segmented
  reporting is based on two business segments &#145;Diabetes care&#146; and &#145;Biopharmaceuticals&#146;.
  Please refer to Note 4 in our <i>Annual Report 2006</i> for details on segmented
  results. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Inflation </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Inflation for the three
  most recent fiscal years has not had a material impact on the Group&#146;s net
  sales and revenues or on net profit. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Foreign currencies
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">The major part of Novo Nordisk&#146;s
  sales is in foreign currencies, mainly EUR, USD, JPY and GBP. The predominant
  part of the production costs and research and development costs, though, are
  in DKK. As a consequence, Novo Nordisk has a significant exposure to foreign
  exchange risks and engages in significant hedging activities, where the most
  significant exposure and hedging are relating to USD, JPY and GBP. For further
  description of foreign currency exposure and hedging activities, please see
  the description of Derivative financial instruments in Note 36 in our <i>Annual
  Report</i> 2006.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Governmental policies
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Please refer to pages 110-111
  Risk Management in our <i>Annual Report 2006</i> for a description of pressure
  on health care costs.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>LIQUIDITY AND
  CAPITAL RESOURCES</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk maintains
  a centralized approach to the management of the Group&#146;s financial risks.
  The overall objectives and policies for Novo Nordisk&#146;s financial risk management
  are outlined in the Novo Nordisk Treasury Policy, which is approved by the Board
  of Directors. The Treasury Policy governs the Group&#146;s use of financial
  instruments, please refer to Item 11. </font></p>
<p><font face="Times New Roman, Times, serif" size="2"><b>Financial resources
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">It is part of Novo Nordisk&#146;s
  Treasury Policy to maintain sufficient financial resources for its present working
  capital. At 31 December 2006, the Group&#146;s DKK 11,442 million of financial
  resources consisted of cash and cash equivalents of DKK 2,985 million, bonds
  with original term to maturity of more than three months of DKK 1,001 million
  and of undrawn committed credit facilities of DKK 7,456 million. The undrawn
  committed credit facilities consist of a EUR 600 million and a EUR 400 million
  facility committed by a number of Danish and international banks. These facilities
  mature in 2012 and 2009, respectively. Cash and cash equivalents consist primarily
  of bank deposits and short-term government bonds. The Group had long-term debt
  of DKK 1,174 million at 31 December 2006. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Cash flow </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Cash flow from operating
  activities for 2006 amounted to DKK 7,738 million compared to DKK 8,712 million
  in 2005. The decrease is primarily due to higher tax payments in 2006. Please
  refer to the consolidated cash flow in Item 17. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">There are no material
  restrictions on the ability of subsidiaries to transfer funds to the Company.
  </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Debt financing </b>
  </font><br>
  <font size="2" face="Times New Roman, Times, serif">Debt financing is obtained
  in DKK and in foreign currencies. Please refer to Notes 22 and 26 in our <i>Annual
  Report 2006</i> for information on currency structure, interest rate structure
  and maturity profile.</font></p>
<p align="center"><font size="2" face="Times New Roman, Times, serif">13</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_14"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">Furthermore, Novo Nordisk&#146;s
  Japanese subsidiary has asset securitization programs with two credit institutions.
  Under these asset securitization programs, the majority of the trade debtors
  in the Japanese subsidiary are sold to accelerate the receipt of cash related
  to those receivables. On part of the sold receivables, Novo Nordisk has issued
  a credit guarantee of up to 15% of the sold trade debtors. The credit guarantee
  is recognized in the balance sheet. For the Novo Nordisk Group these programs
  are not of material importance for liquidity.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Financial instruments
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Novo Nordisk does not enter
  into speculative positions and only hedges commercial exposure. The financial
  instruments used in conjunction with the Group&#146;s financial risk management
  include currency forwards, currency options, interest rate swaps and cross-currency
  swaps. Short- and long-term </font><font size="2" face="Times New Roman, Times, serif">debt
  as well as money-market deposits are also used in the financial risk management.
  Please refer to Note 36 in our <i>Annual Report 2006</i> for further information
  on financial instruments including currency and interest rate structure. </font></p>
<font face="Times New Roman, Times, serif" size="2"> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Commitments for capital
  expenditure etc. </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Contractual obligations
  for capital expenditure and other contingent liabilities at 31 December 2006
  and 31 December 2005 are shown in Note 37 of the consolidated financial statements
  in our <i>Annual Report 2006</i>. The Group has overall contractual obligations
  related to investments in fixed assets of DKK 64 million compared to DKK 65
  million in 2005. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Additionally, the Group
  has contractual obligations of DKK 2,313 million relating to research and development
  projects, compared to DKK 1,241 million in 2005. Please refer to Note 37 in
  our <i>Annual Report 2006 </i>for a description of these commitments and other
  contingencies. The Executive Management of the Group believes that the obligations
  are covered by the Group&#146;s financial resources as well as expected future
  cash flows generated from operating activities. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>RESEARCH AND
  DEVELOPMENT, PATENTS AND LICENSES, ETC.</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk&#146;s research
  activities utilize biotechnological methods based on genetic engineering, advanced
  protein chemistry and protein engineering (molecular modeling). These methods
  have played a key role in the development of the production technology which
  is used in the manufacturing of insulin, recombinant factor VIIa, human growth
  hormone and glucagon. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk&#146;s research
  and development facilities are mainly located in Denmark, but development activities
  also take place in other countries. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Research and development
  expenditures during 2006 were DKK 6.3 billion or 16.3% of sales, while research
  and development expenditures in 2005 and 2004 were DKK 5.1 billion or 15.1%
  of sales and DKK 4.4 billion or 15.0% of sales, respectively. Novo Nordisk&#146;s
  research and development organization comprised approximately 4,000 employees
  at the end of 2006. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk expects its
  research and development expenditure to increase as a percentage of sales, due
  to several major projects in late phase development, which is typically the
  most expensive phase. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk has decided
  to discontinue R&amp;D activities within the oral antidiabetic (OAD) segment
  and, instead, focus exclusively on therapeutic proteins, a key competence area
  for the company. As a consequence, all existing pre-clinical and clinical OAD
  projects, including NN9101 (a glucokinase activator project currently in phase
  1 clinical testing) are expected to be out-licensed. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Information relating to
  selected research and development projects, set forth on pages 18-19 and 34-35
  in our <i>Annual Report 2006</i>, is incorporated herein by reference.</font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">14</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_15"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif"><b><i><u>TREND INFORMATION</u>
  </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">As a pharmaceutical company
  Novo Nordisk has benefited from changes in demographics such as the increasing
  share of elderly people. Moreover, the growing problem of obesity both in the
  western world and the developing world is resulting in a significant increase
  in the number of people with diabetes. In 2006, approximately 230 million people
  worldwide in the adult population (age group 20-79) were estimated to have diabetes
  and 310 million people to have prediabetes. According to the International Diabetes
  Federation, the number of people with diabetes is expected to increase to 350
  million in the adult population by 2025. Diabetes care is Novo Nordisk&#146;s
  largest segment comprising approximately 72% of sales. The epidemic growth in
  the number of people with diabetes, a continuing transition from human insulin
  to modern insulin (insulin analogues) and new delivery devices, as well as market
  share gains are driving the growth of the diabetes care segment. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The other segment of the
  Company is biopharmaceuticals, which consists of haemostasis management, growth
  hormone therapy and other biopharmaceutical products. Within haemostasis management
  the penetration of NovoSeven<sup>&reg;</sup> has continued and the franchise
  has shown double-digit sales growth since launch. The growth hormone therapy
  franchise has benefited from further penetration and increasing market share
  of Norditropin<sup>&reg; </sup>a liquid, ready to use formulation.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">For further information
  on trends please refer to the &#145;Management report and discussion&#146; on
  pages 8-15 in our <i>Annual Report 2006</i>.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Information about the
  expectations for the financial year 2007 can be found in our <i>Annual Report
  2006</i> on pages 8-15 in the section &#145;Management report and discussion&#146;
  2006. Information about the Company&#146;s long-term financial targets can be
  found in the &#145;Management report and discussion&#146; on page 8-15.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Significant changes
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Novo Nordisk 15 January
  2007 announced a decision to focus all its R&amp;D resources on the company&#146;s
  growing pipeline of protein-based pharmaceuticals. As a result, the company&#146;s
  R&amp;D activities within small molecules for oral treatment of diabetes will
  be discontinued and existing projects divested. Since 2002, Novo Nordisk has
  increased its focus on pharmaceuticals based on therapeutic proteins, and today
  the company&#146;s pipeline of protein-based pharmaceuticals within diabetes,
  haemostasis, growth disorders and other diseases is larger than ever. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The decision will have
  a direct impact on approximately 180 employees in Denmark, primarily in the
  Diabetes Research Unit, and to a smaller extent in the CMC Supply unit and within
  Global Development. Novo Nordisk currently estimates that it will be possible
  to offer other positions within the company to approximately half of the affected
  employees. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>OFF-BALANCE SHEET
  ARRANGEMENTS</u></i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk has an off-balance
  sheet arrangement which is a credit guarantee in connection with an asset securitization.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk&#146;s Japanese
  subsidiary has asset securitization programs with two external credit institutions.
  Please refer also to Item 5 &#145;Debt financing&#146;. </font></p>
<table width="100%" align="center" border=1 cellspacing=0 cellpadding=0>
  <tr>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;DKK
        million</b></font></div>
    </td>
    <td align="center" width="10%"><font face="Times New Roman, Times, serif" size="2"><b>2003</b></font></td>
    <td align="center" width="10%"><font face="Times New Roman, Times, serif" size="2"><b>2004</b></font></td>
    <td align="center" width="10%"><font face="Times New Roman, Times, serif" size="2"><b>2005</b></font></td>
    <td align="center" width="10%"><font face="Times New Roman, Times, serif" size="2"><b>2006</b></font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Sold trade
      debtors with credit guarantee</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">1,228</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">1,398</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">1,563</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">1,515</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Credit
      guarantee</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">50</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">61</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">112</font></td>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">100</font></td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">For further information
  on contingencies, reference is made to Note 37 in our <i>Annual Report 2006</i>.</font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">15</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_16"></a> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>TABULAR DISCLOSURE
  OF CONTRACTUAL OBLIGATIONS</u> </i></b> </font></p>
<table width="100%" align="center" border=1 cellspacing=0 cellpadding=0>
  <tr>
    <td rowspan="2" valign="top"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Contractual
      obligations</b></font><font face="Times New Roman, Times, serif" size="2"><b><br>
      &nbsp;&nbsp;DKK million</b></font></td>
    <td align="center" colspan="5">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>Payments
        due by period</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="center" width="15%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>Less
        than</b></font><font face="Times New Roman, Times, serif" size="2"><b><br>
        1 year</b></font></div>
    </td>
    <td align="center" width="15%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>1&#150;3</b></font></div>
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>years</b></font></div>
    </td>
    <td align="center" width="15%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>3&#150;5</b></font></div>
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>years</b></font></div>
    </td>
    <td align="center" width="15%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>More
        than</b></font></div>
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>5
        years</b></font></div>
    </td>
    <td align="center" width="15%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>Total</b></font></div>
      <div align="center"></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Long-term
      debt</font></td>
    <td align="center">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">12</font></div>
    </td>
    <td align="right">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">160</font></div>
    </td>
    <td align="right">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">511</font></div>
    </td>
    <td align="center">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">503</font></div>
    </td>
    <td align="center">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>1,186</b></font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Operating
      leases</font></td>
    <td align="center">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">651</font></div>
    </td>
    <td align="right">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">990</font></div>
    </td>
    <td align="right">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">625</font></div>
    </td>
    <td align="center">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">602</font></div>
    </td>
    <td align="center">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>2,868</b></font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Defined
      benefit plan</font></td>
    <td align="center">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">0</font></div>
    </td>
    <td align="right">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">0</font></div>
    </td>
    <td align="right">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">0</font></div>
    </td>
    <td align="center">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">330</font></div>
    </td>
    <td align="center">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>330</b></font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;&nbsp;Purchase
      obligations</font></td>
    <td align="center">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>783</b></font></div>
    </td>
    <td align="right">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>149</b></font></div>
    </td>
    <td align="right">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>3</b></font></div>
    </td>
    <td align="center">
      <div align="center"><font size="2" face="Times New Roman, Times, serif"><b>0</b></font></div>
    </td>
    <td align="center">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>935</b></font></div>
    </td>
  </tr>
  <tr>
    <td><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Total</b></font></td>
    <td align="center">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>1,446</b></font></div>
    </td>
    <td align="right">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>1,299</b></font></div>
    </td>
    <td align="right">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>1,139</b></font></div>
    </td>
    <td align="center">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>1,435</b></font></div>
    </td>
    <td align="center">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>5,319</b></font></div>
    </td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">For further information
  on contractual obligations to research and development of 2,313 million DKK
  please refer to Item 5 and to Note 37 in our <i>Annual Report 2006</i>. </font></p>
<p><font face="Times New Roman, Times, serif" size="2"><b><i><u>Safe Harbor</u>
  </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p>&nbsp;</p>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p16"></a>ITEM
  6 DIRECTORS, SENIOR MANAGEMENT<sup>3</sup> AND EMPLOYEES </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>DIRECTORS AND
  EXECUTIVE MANAGEMENT</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Reference is made to pages
  112-113 in our <i>Annual Report 2006</i> for name, position, date of birth and
  period of service as director for the members of the Board of Directors. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Reference is made to page
  114 for name, position, date of birth, year of appointment and year of joining
  Novo Nordisk for the members of Executive Management. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The Board of Directors
  has the overall responsibility for the affairs of the Company. The Board ordinarily
  meets seven times a year for the purpose of dealing with the principal issues
  of the Company&#146;s business and to establish and review general policies
  for the conduct of the Company&#146;s business. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The business address of
  the Board of Directors and Executive Management is Novo Nordisk A/S, Novo All&eacute;
  1, DK-2880 Bagsv&aelig;rd, Denmark. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The activities of the
  directors and members of Executive Management outside the Company are included
  in our <i>Annual Report 2006</i> on pages 112-113. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">There are no family relationships
  between the Board of Directors, Executive Management or between any of the members
  of the Board of Directors and any member of Executive Management. No director
  or member of Executive Management is elected according to an arrangement or
  understanding with customers, suppliers or others. As required by the Danish
  Companies Act, directors are elected at General Meetings by simple majority
  vote. In addition, four employee representatives are elected for four year terms
  by the employees in the Danish companies.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>COMPENSATION</u>
  </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Reference is made to Notes
  34 and 35 in our <i>Annual Report 2006</i> regarding compensation.</font></p>
<table width="100%" cellspacing="0" cellpadding="0">
  <tr>
    <td width="3%">
      <hr noshade size=1>
    </td>
    <td width="10%">
      <hr noshade size=1>
    </td>
    <td>&nbsp; </td>
  </tr>
  <tr>
    <td width="3%"><font size="1" face="Times New Roman, Times, serif">3 </font></td>
    <td colspan="2"><font size="1" face="Times New Roman, Times, serif">In this
      document the term Senior Management refers to Executive Management in our
      <i>Annual Report 2006</i>. </font></td>
  </tr>
</table>
<p>&nbsp;</p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">16</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_17"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif"><b><i><u>BOARD PRACTICES</u>
  </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Reference is made to our
  <i>Annual Report 2006</i> page 108-109, regarding board practices. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>EMPLOYEES</u>
  </i></b></font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Reference is made to the
  section titled &#145;Summary of financial data 2002-2006&#146; pages 102-103
  in our <i>Annual Report 2006 </i>regarding the total number of full-time employees
  in Novo Nordisk at year-end for the years 2002-2006. </font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td><font face="Times New Roman, Times, serif" size="2"><b>Employees</b></font></td>
    <td align="center" width="2%">&nbsp;</td>
    <td align="center" width="8%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>2002</b></font></div>
    </td>
    <td align="center" width="2%">&nbsp;</td>
    <td align="center" width="8%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>2003</b></font></div>
    </td>
    <td align="center" width="2%">&nbsp;</td>
    <td align="center" width="8%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>2004</b></font></div>
    </td>
    <td align="center" width="2%">&nbsp;</td>
    <td align="center" width="8%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>2005</b></font></div>
    </td>
    <td align="center" width="2%">&nbsp;</td>
    <td align="center" width="8%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>2006</b></font></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right">
      <hr noshade size=1>
    </td>
    <td align="right">&nbsp;</td>
    <td align="right">
      <hr noshade size=1>
    </td>
    <td align="right">&nbsp;</td>
    <td align="right">
      <hr noshade size=1>
    </td>
    <td align="right">&nbsp;</td>
    <td align="right">
      <hr noshade size=1>
    </td>
    <td align="right">&nbsp;</td>
    <td align="right">
      <hr noshade size=1>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Employees outside
      Denmark as a percentage of total number of employees</font></td>
    <td align="right">&nbsp;</td>
    <td align="right">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">38%</font></div>
    </td>
    <td align="right">&nbsp;</td>
    <td align="right">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">39%</font></div>
    </td>
    <td align="right">&nbsp;</td>
    <td align="right">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">41%</font></div>
    </td>
    <td align="right">&nbsp;</td>
    <td align="right">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">45%</font></div>
    </td>
    <td align="right">&nbsp;</td>
    <td align="right">
      <div align="center"><font size="2" face="Times New Roman, Times, serif">47%</font></div>
    </td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">Executive Management believes
  that the Company has a good relationship with its employees in general and with
  the labor unions of the Novo Nordisk employees. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk believes
  that the current personel policy results in low staff turnover, high morale,
  and ease in recruiting new employees. The Company has not experienced any significant
  labor disputes.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>SHARE OWNERSHIP</u></i></b>
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Since 1998, Novo Nordisk
  has established share based incentive schemes for Executive Management and other
  key executives of the Company and its affiliates. The share based incentive
  schemes provide for annual grants contingent on the fulfillment of performance
  and shareholder value related goals based on long-term financial and non-financial
  targets. For information on the Board of Directors&#146; and Executive Management&#146;s
  individual holdings of share options, exercise of options and granting of shares,
  please refer to Note 35 in our <i>Annual Report 2006</i>. The members of the
  Board of Directors and Executive Management and key management executives in
  the aggregate hold less than one percent of the beneficial ownership of the
  company. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">For information on the
  Board of Directors&#146; and Executive Management&#146;s individual holdings
  of and trading in Novo Nordisk shares during 2006, please refer to Note 35 in
  our <i>Annual Report 2006</i>. As of 30 January 2007 the Board of Directors
  and Executive Management owned 60,767 B shares. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The total number of options
  to acquire B shares held by Executive Management and Board of Directors as of
  30 January 2007 equals 200,560, and the specific conditions can be summarized
  as follows: </font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b><u>Share
        option plan</u></b></font></div>
    </td>
    <td align="center" width="27%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b><u>Number
        of options held</u></b></font></div>
    </td>
    <td width="2%">&nbsp;</td>
    <td align="center" width="18%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b><u>Exercise
        price</u></b></font></div>
    </td>
    <td width="2%">&nbsp;</td>
    <td align="center" width="32%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b><u>Exercise
        period</u></b></font></div>
    </td>
  </tr>
  <tr>
    <td align="center">&nbsp;</td>
    <td align="center">&nbsp;</td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><u><font face="Times New Roman, Times, serif" size="2"><b>(DKK)</b></font></u></div>
    </td>
    <td><u></u></td>
    <td align="center">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">1998 Ordinary</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">3,750</font></td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">125</font></div>
    </td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">03.25.2002
      &#150; 03.24.2007 *)</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">1999 Ordinary</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">32,000</font></td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">198</font></div>
    </td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">03.24.2003
      &#150; 03.23.2008</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">2000 Ordinary</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">29,000</font></td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">198</font></div>
    </td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">02.22.2004
      &#150; 02.21.2009</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">2000 Launch</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">35,560</font></td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">198</font></div>
    </td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">02.01.2004
      &#150; 01.31.2007 *)</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">2001 Ordinary</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">40,250</font></td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">332</font></div>
    </td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">02.08.2005
      &#150; 02.07.2010</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">2003 Ordinary</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">60,000</font></td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">195</font></div>
    </td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">02.06.2007
      &#150; 02.05.2012</font></td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">*) For 3,750 1998 Ordinary
  share options and 35,560 2000 Launch share options, the Board of Directors has
  extended the exercise period to 3 August 2007. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">For a full description
  of individual holdings and exercise of stock options, please refer to Notes
  34 and 35 in our <i>Annual Report 2006</i>. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In the period from 1 January
  2007 until 30 January 2007, no B shares were sold or purchased by the members
  of the Board of Directors or Executive Management, and no options have been
  exercised. The internal rules on trading in Novo Nordisk securities by members
  of the Board of Directors and </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">17</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_18"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">Executive Management only
  permit trading in the 15 calendar-day period following each quarterly announcement.
  </font></p>
<p>&nbsp; </p>
<p><font face="Times New Roman, Times, serif" size="2"><a name="#p18"></a>ITEM
  7 MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>MAJOR SHAREHOLDERS</u>
  </i></b></font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The total share capital
  of the Company is split in two classes, A shares and B shares, each with different
  voting rights. The A shares have 10 votes per DKK 1 of the A share capital and
  the B shares have one vote per DKK 1 of the B share capital. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">All of the A shares of
  the Company are held by Novo A/S, a wholly-owned subsidiary of the Novo Nordisk
  Foundation (the &#145;Foundation&#146;). As of 31 December 2006, the A shares
  represented approximately 67% of the votes exercisable at the Annual General
  Meeting. Treasury shares have no votes at the Annual General Meeting. </font></p>
<p><font size="2" face="Times New Roman, Times, serif">The Foundation is a self-governing
  and self-owned organization whose main purposes are to be a stable base for
  the business and research activities of the subsidiaries of Novo A/S, and to
  support medical research and other scientific, humanitarian and social objectives.
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo A/S was established
  in September 1999 with a contribution in kind of interest-bearing securities
  from the Foundation. In December 1999, the Foundation contributed its total
  holdings of A and B shares in Novo Nordisk A/S to Novo A/S in return for shares
  in Novo A/S. The purpose of Novo A/S is to administer its portfolio of securities
  and minority capital interests and to administer and vote on the A shares and
  B shares in Novo Nordisk A/S, thereby creating a satisfactory financial return
  for the Foundation. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Under its statutes (Articles
  of Association), the Foundation is governed by a Board of Governors, which must
  be comprised of at least six and not more than 12 members, and at least two
  members must have a medical or scientific background. Members of the Foundation&#146;s
  Board of Governors are typically nominated by the chairman and elected by a
  two-thirds vote of the elected members. Any member may be removed by unanimous
  vote of the other members of the Foundation&#146;s Board of Governors. In addition,
  employee representatives are elected for four-year terms by the employees of
  the subsidiaries of the Foundation, in accordance with Danish law, which provides
  that the employees of the Danish subsidiaries are entitled to be represented
  by at least half of the number of members who have themselves been elected under
  the Articles of Association. No person or entity exercises any kind of formal
  influence over the Foundation&#146;s Board. The Foundation&#146;s Board currently
  consists of nine persons, three of whom are also members of the Board of Directors
  of Novo Nordisk A/S (Kurt Anker Nielsen, Stig Str&oslash;b&aelig;k and S&oslash;ren
  Thuesen Pedersen).</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Under its statutes, Novo
  A/S is governed by a Board of Directors, which must be comprised of at least
  three and not more than six members who are elected annually by shareholder
  vote. According to the Foundation&#146;s statutes, its Board of Governors can
  and shall provide for members of its own Board of Governors to be elected to
  Novo A/S&#146; Board of Directors. Novo A/S&#146;s Board of Directors currently
  has four members, with two directors who are also members of the Board of the
  Foundation (Ulf Jo-hansson and J&oslash;rgen Boe) and one director who is also
  a member of the Board of Directors of Novo Nordisk A/S (G&ouml;ran Ando). The
  Chairman of the Foundation&#146;s Board of Governors serves as the Chairman
  of Novo A/S&#146; Board of Directors.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">According to the statutes,
  the Foundation, in exercising its voting rights through Novo A/S at Novo Nordisk
  A/S&#146; General Meetings, must vote with regard for what&#146;s in Novo Nordisk&#146;s
  best interest. A shares held by Novo A/S cannot be sold or be subject to any
  disposition so long as the Foundation exists. The dissolution of the Foundation
  or any change in its objectives requires the unanimous vote of the Foundation&#146;s
  Board of Governors. Other changes in the Foundation&#146;s statutes require
  the approval of two-thirds of the members of the Foundation&#146;s Board of
  Governors. In addition, changes in </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">18</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_19"></a> </font>
<p><font size="2" face="Times New Roman, Times, serif">the Foundation&#146;s statutes
  require approval of the Danish Foundation Authorities.<b> </b>According to the
  statutes, the Foundation is required to maintain material influence over Novo
  Nordisk A/S and its majority vote in Novo A/S. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The B shares of the Company
  are registered with V&aelig;rdipapir Centralen (VP Securities Services) and
  are not represented by certificates. Generally, V&aelig;rdipapir Centralen does
  not provide the Company with information with respect to registration. However,
  set forth below is information as of 12 January 2007 with respect to (a) any
  shareholder who is known to the Company to be the owner of more than 5% of any
  class of the Company&#146;s securities and (b) the total amount of any class
  owned by the directors and Executive Management as a group: </font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td>&nbsp;</td>
    <td align="center" width="2%">&nbsp;</td>
    <td align="center" width="34%">&nbsp;</td>
    <td align="center" width="2%">&nbsp;</td>
    <td align="center" width="14%">&nbsp;</td>
    <td align="center" width="2%">&nbsp;</td>
    <td align="center" width="19%">&nbsp;</td>
    <td width="2%">&nbsp;</td>
    <td align="center" width="13%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>Percent
        of</b></font></div>
    </td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b><u>Title
        of class</u></b></font></div>
    </td>
    <td align="center">&nbsp;</td>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b><u>Identity
        of person or group</u></b></font></div>
    </td>
    <td align="center">&nbsp;</td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b><u>Shares
        owned</u></b></font></div>
    </td>
    <td align="center">&nbsp;</td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b><u>Percent
        of class</u></b></font></div>
    </td>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b><u>total
        votes</u></b></font></div>
    </td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">A shares</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Novo A/S</font></td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">53,743,600</font></td>
    <td><font face="Times New Roman, Times, serif" size="2"><sup>4</sup></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">100.00</font></td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">67.10</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">B shares</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Novo A/S</font></td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">32,181,200</font></td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">11.36</font></td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">4.02</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">B shares</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">The Capital Group
      Companies Inc.</font></td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">43,919,720</font></td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">15.51</font></td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">5.48</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">B shares</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Novo Nordisk A/S and
      affiliates (treasury shares)</font></td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">19,713,069</font></td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">6.96</font></td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0.00</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">B shares</font></td>
    <td>&nbsp;</td>
    <td><font size="2" face="Times New Roman, Times, serif">Board of Directors
      and Executive Management</font></td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">60,767</font></td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0.02</font></td>
    <td>&nbsp;</td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0.01</font></td>
    <td>&nbsp;</td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">In January 2006, Novo
  Nordisk announced a share buy-back scheme of DKK 6 billion. At the end of 2006,
  7,468,957 shares corresponding to DKK 3 billion had been repurchased. In January
  2007, Novo Nordisk announced an increase by DKK 4 billion in the ongoing DKK
  6 billion share repurchase programme, bringing the total value of the share
  repurchase programme to DKK 10 billion. The programme is now expected to be
  finalised by the end of 2008 as compared to the previously communicated completion
  time by the end of 2007.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">After the shareholders&#146;
  approval at the Annual General Meeting on 8 March 2006 of the proposed reduction
  of the company&#146;s share capital, 17,734,160 shares were cancelled in June,
  reducing the number of treasury shares accordingly. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">As the B shares are in
  bearer form, it is not possible to give an accurate breakdown of the holdings
  and number of shareholders per country. It is, however, estimated that approximately
  57% of the B share capital was held in Denmark at the end of 2006. Approximately
  25% of the B share capital is estimated to be held in North America. The estimated
  total number of shareholders is more than 80,000 of which more than 60,000 are
  estimated to be Danish residents and 10,000 to be resident in the United States
  of America.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>RELATED PARTY
  TRANSACTIONS</u></i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Related parties are considered
  to be the Novo Nordisk Foundation, Novo A/S, the Novozymes Group (due to shared
  controlling shareholder, Novo A/S), associated companies, the Board of Directors
  and officers of these entities and Management of Novo Nordisk. Novo Nordisk
  has access to certain assets of and can purchase certain services from Novo
  A/S and the Novozymes Group and vice versa. All agreements relating to such
  assets and services are based on the list prices used for sales to third parties
  where such list prices exist, or the price has been set at what is regarded
  as market price. The material terms of these agreements are renegotiated annually.</font></p>
<table width="100%" cellspacing="0" cellpadding="0">
  <tr>
    <td width="3%">
      <hr noshade size=1>
    </td>
    <td width="10%">
      <hr noshade size=1>
    </td>
    <td>&nbsp; </td>
  </tr>
  <tr valign="top">
    <td width="3%"><font size="1" face="Times New Roman, Times, serif">4 </font></td>
    <td colspan="2"><font size="1" face="Times New Roman, Times, serif">The number
      of A shares is calculated as an equivalent of the trading size (DKK 2) of
      the listed B shares but is not formally divided into number of shares. The
      A shares are not listed on any stock exchange. </font></td>
  </tr>
</table>
<p>&nbsp;</p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">19</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_20"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">In August 2006 Novo Nordisk
  A/S acquired 4,522,462 B-shares, worth DKK 1.8 billion, from Novo A/S as part
  of the ongoing DKK 6 billion share repurchase program. The transaction price
  was DKK 405.79 per share and was calculated as the average market price from
  3 August to 17 August 2006 in the open window, following the announcement of
  the financial results for the second quarter of 2006.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Related party transactions
  in 2006, 2005 and 2004 are primarily payments for services provided between
  the Novo Nordisk Group and the Novozymes Group and transactions with associated
  companies. The financial impact of these transactions is limited.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In 2005 and 2006 the total
  DKK amount of transactions with associated companies decreased, primarily due
  to lower level of acquired intellectual property rights from associated companies.
  There have not been any significant transactions with related parties out of
  the ordinary course of business since </font><font size="2" face="Times New Roman, Times, serif">31
  December 2006. For further information please refer to Note 33 in our <i>Annual
  Reports 2005 and 2006</i>.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In 2004, the total DKK
  amount of transactions with associated companies has increased, primarily due
  to the acquisition of certain intangible property rights from associated companies.
  For further information please refer to Note 37 in our <i>Annual Report 2004</i>.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">There have not been and
  are no loans to the Board of Directors or Executive Management in 2004, 2005
  and 2006.</font></p>
<p>&nbsp;</p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>INTERESTS OF
  EXPERTS AND COUNSEL</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p20"></a>ITEM
  8 FINANCIAL INFORMATION </font></p>
<p>&nbsp;</p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>CONSOLIDATED
  STATEMENTS AND OTHER FINANCIAL INFORMATION</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">See Item 17, &#145;Financial
  statements&#146; for information on balance sheet, income statement, changes
  in shareholders&#146; funds, cash flow statement, related notes, etc., including
  comparative figures.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">For information on net
  turnover by business segments and geographic segments, see Item 4, &#145;Business
  overview&#146;.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Dividend policy </b>
  </font><br>
  <font size="2" face="Times New Roman, Times, serif">At the Annual General Meeting
  on 7 March 2007, the Board of Directors will propose a dividend of DKK 7.00
  per share. No dividends will be paid on the Company&#146;s holding of its treasury
  shares. It is the intention of the Board of Directors that, over time, the payout
  ratio of Novo Nordisk shall be at the level of comparable companies. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Legal proceedings</b>
  </font><br>
  <font size="2" face="Times New Roman, Times, serif">Reference is made to Note
  37 in our Annual Report<i> </i>2006 regarding legal proceedings. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Significant changes
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Reference is made to Note
  37 in our Annual Report<i> 2006</i> for significant events after the balance
  sheet date. For information on important events in the financial year of 2006,
  please refer to &#145;Important events in 2006&#146; under Item 4. </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">20</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_21"></a> </font>
<p><font face="Times New Roman, Times, serif" size="2"><a name="#p21"></a>ITEM
  9 THE OFFER AND LISTING</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Offer and listing details
  </b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The table below sets forth
  for the calendar periods indicated, in the first two columns, high and low prices
  for the B shares as reported by the Copenhagen Stock Exchange and, in the third
  and fourth columns, high and low ADR prices as reported by the New York Stock
  Exchange. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Following the change in
  trading units as of 4 April 2001, all quotes are restated to reflect the new
  trading unit of DKK 2 per B share and a ratio of B shares to ADRs of 1:1. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif"></font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td>&nbsp;</td>
    <td align="center" colspan=3>
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>DKK
        per B share</b></font></div>
    </td>
    <td width="2%">
      <div align="right"></div>
    </td>
    <td align="center" colspan=3>
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>USD
        per ADR</b></font></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td colspan=3>
      <hr noshade size=1 align="right">
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td colspan=3>
      <hr noshade size=1 align="right">
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>High</b></font></div>
    </td>
    <td width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>Low</b></font></div>
    </td>
    <td width="5%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>High</b></font></div>
    </td>
    <td width="2%">
      <div align="right"></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>Low</b></font></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">2002</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">340</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">168</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">40.60</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">21.50</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">2003</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">251</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">174</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">41.23</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">25.10</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">2004</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">331</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">230</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">55.28</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">39.03</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">2005</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">356</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">282</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">60.10</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">48.05</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">2006</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">479</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">339</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">84.65</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">54.79</font></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
  </tr>
  <tr>
    <td><font face="Times New Roman, Times, serif" size="2"><b>2005</b></font></td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">1st Quarter</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">325</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">282</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">58.74</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">49.22</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">2nd Quarter</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">340</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">292</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">60.10</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">49.59</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">3rd Quarter</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">332</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">302</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">55.69</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">48.05</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">4th Quarter</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">356</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">304</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">56.72</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">48.54</font></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
  </tr>
  <tr>
    <td><font face="Times New Roman, Times, serif" size="2"><b>2006</b></font></td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">1st Quarter</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">395</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">339</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">63.93</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">54.79</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">2nd Quarter</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">406</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">343</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">68.31</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">57.65</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">3rd Quarter</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">439</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">360</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">75.34</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">61.01</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">4th Quarter</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">479</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">423</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">84.65</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">71.41</font></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">July 2006</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">375</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">360</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">64.59</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">61.01</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">August 2006</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">431</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">364</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">74.23</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">62.03</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">September 2006</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">439</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">420</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">75.34</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">72.00</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">October 2006</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">467</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">423</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">78.67</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">71.41</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">November 2006</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">452</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">429</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">78.62</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">75.16</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">December 2006</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">479</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">434</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">84.65</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">77.60</font></div>
    </td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">1-26 January 2007</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">492</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">466</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">86.25</font></div>
    </td>
    <td>
      <div align="right"></div>
    </td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">77.67</font></div>
    </td>
  </tr>
</table>
<p>&nbsp; </p>
<p><font face="Times New Roman, Times, serif" size="2"><b><i><u>PLAN OF DISTRIBUTION</u>
  </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable.</font></p>
<p>&nbsp; </p>
<p><font face="Times New Roman, Times, serif" size="2"><b><i><u>MARKETS</u> </i></b>
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The Company&#146;s share
  capital consists of A shares and B shares. As described above, the A shares
  are owned by the Novo Nordisk Foundation through its wholly owned company Novo
  A/S and are not listed or traded on any stock exchange. The B shares have been
  publicly traded since 1974 and have </font><font face="Times New Roman, Times, serif" size="2">
  </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">21</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_22"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">been listed on the Copenhagen
  Stock Exchange since that time and on the London Stock Exchange since 1978.
  The Copenhagen Stock Exchange is the principal trading market for the B shares.
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">American Depositary Receipts
  (&#145;ADRs&#146;) representing the B shares, as evidenced by American Depositary
  Receipts issued by JP Morgan Chase Bank of New York, as the Depositary, have
  been listed on the New York Stock Exchange since 1981. As of 31 December 2006,
  14,954,354 B share equivalents (representing 5.3 % of the outstanding B shares,
  adjusted for the treasury shares) were held in the form of ADRs. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>SELLING SHAREHOLDERS</u>
  </i></b></font></p>
<p><font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>DILUTION</u>
  </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>EXPENSES OF THE
  ISSUE</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p>&nbsp; </p>
<p><font face="Times New Roman, Times, serif" size="2"><a name="#p22"></a>ITEM
  10 &nbsp;&nbsp;ADDITIONAL INFORMATION </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>SHARE CAPITAL</u>
  </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>MEMORANDUM AND
  ARTICLES OF ASSOCIATION</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">At the General Annual
  Meeting 8 March 2006, it was decided to make a reduction of the company&#146;s
  B share capital from DKK 601,901,120 to DKK 566,432,800. The company&#146;s
  share capital hereafter amount to DKK 673,920,000 divided into A share capital
  of DKK 107,487,200 and B share capital of DKK 566,432,800. A new article 8.5
  was adopted stating: </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">&#147;The Board of Directors
  may decide that a General Meeting shall be conducted in the English language.
  All documents, which shall be made available for the shareholders, shall be
  available in Danish as well the English language. The Board of Directors shall
  secure that the Danish shareholders, attending a General Meeting, can participate
  in the General Meeting in Danish.&#148; </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">All other articles remain
  unchanged. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>MATERIAL CONTRACTS</u>
  </i></b></font></p>
<p> <font size="2" face="Times New Roman, Times, serif">There have been no material
  contracts outside the ordinary course of business. For a description of other
  contracts, please see the description under Item 4 &#150; &#145;Important events&#146;.<b>
  </b> </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>EXCHANGE CONTROLS</u></i></b>
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">There are no governmental
  laws, decrees, or regulations in Denmark (including, but not limited to, foreign
  exchange controls) that restrict the export or import of capital, or that affect
  the remittance of dividends, interest or other payments to non-resident holders
  of the B shares or the American Depositary Receipts. </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">22</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_23"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">There are no limitations
  on the right of non-resident or foreign owners to hold or vote the B shares
  or the American Depositary Receipts imposed by the laws of Denmark or the Articles
  of Association of the Company.<b> </b> </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>TAXATION</u></i></b><i>
  </i> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The following summary
  outlines certain US and Danish tax consequences to holders of ADRs or B shares
  who are citizens or residents of the United States under the current Convention
  between the Government of the United States of America and the Government of
  the Kingdom of Denmark for the Avoidance of Double Taxation and the Prevention
  of Fiscal Evasion with Respect to Taxes on Income (the &#145;Current Convention&#146;).
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">For purposes of the United
  States Jobs and Growth Tax Relief Reconciliation Act of 2003 (P-L. 108-27, 117
  Stat. 752) and the Internal Revenue Code of 1986, as amended (the &#145;US Code&#146;),
  and the Current Convention, the holders of ADRs will be treated as the owners
  of the underlying B shares. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Under the traditional
  Danish tax procedure, withholding tax is deducted from dividend payments to
  US residents and corporations at a 28% rate, the rate which is generally applicable
  to non-residents in Denmark without regard to eligibility for a reduced treaty
  rate. Under the Current Convention, however, the maximum rate of Danish tax
  which may be imposed on a dividend paid to a US resident or corporation that
  does not have a &#145;permanent establishment&#146; (as defined therein) in
  Denmark is 15%. US residents and corporations who are eligible for the reduced
  treaty rate may apply to the Danish tax authorities to obtain a refund to the
  extent that the withholding tax exceeds the maximum rate. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">As effective in 1987,
  the Danish tax authorities approved the Company&#146;s proposal to simplify
  such procedure. Under the approved procedure, US resident shareholders holding
  ADRs will receive their dividends from the Depositary reduced only by the 15%
  Danish withholding tax provided for in the Current Convention provided they
  certify that they are US residents. Accordingly, US resident shareholders that
  have submitted the required form (Form 6166) to the Depositary will no longer
  have to file for any tax withholding refund from the Danish tax authorities.
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Subject to the limitations
  and conditions provided in the Jobs and Growth Tax Relief Reconciliation Act
  of 2003 (P-L. 108-27, 117 Stat. 752), a US citizen will be taxed at a maximum
  of 15% of the dividend, as received from a Qualified Foreign Corporation (QFC).
  Novo Nordisk A/S is a Qualified Foreign Corporation. It is a condition that
  the ADR holder fulfill certain holding period requirements.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Subject to the limitations
  and conditions provided in the US Tax Code, the ADR holder may elect to credit
  the Danish taxes paid on dividends against its US federal income tax liability.
  The credit includes taxes initially withheld from dividends declared to the
  extent the withheld taxes are not repayable to the United States shareholder.
  For US federal income tax purposes, the full dividend payment, without reduction
  for Danish withholding tax, is treated as a foreign source dividend. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Subject to the limitations
  and conditions provided in the US Tax Code, a US resident or domestic corporation
  may elect to credit any Danish taxes paid on dividends from a Danish corporation
  against its US federal income tax liability. The credit includes taxes initially
  withheld from dividends declared to the extent the withheld taxes are not repayable
  to the US shareholder. Alternatively, subject to applicable limitations, a US
  shareholder may elect to deduct Danish taxes withheld from dividend payments
  which will generally constitute passive income for certain shareholders. For
  US federal income tax purposes, the full dividend payment, without reduction
  for Danish withholding tax, is treated as a foreign source dividend. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Under the US Tax Code,
  any dividend payments received by US corporations from Danish corporations will
  generally be taxable as income and are not eligible for any dividend-received
  deduction. The full amount of dividends declared, without reduction for any
  Danish tax withheld, will be included in the gross income of the recipient US
  Corporation subject to the aforementioned foreign tax credit. </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">23</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_24"></a> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Sales of ADRs or B
  shares </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Any gains or losses derived
  from the sale of ADRs or B shares by an individual that is not a resident of
  Denmark or a non-Danish corporation that is not doing business in Denmark are
  not subject to Danish taxation, but are subject to the general US tax rules
  applicable to such transactions by US citizens, residents or domestic corporations.
  A US shareholder will recognize capital gain or loss for US federal income tax
  purposes on a sale or other disposition of ADRs or B shares in the same manner
  as on the sale or disposition of any other shares. In addition, any non-resident
  of Denmark may remove from Denmark any convertible currency representing the
  proceeds of the sales of ADRs or B shares in Denmark. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The foregoing sections
  offer a general description and you are urged to consult your own tax advisers
  to determine the U.S. federal, state local and foreign tax consequences of purchasing,
  owning and disposing of class B shares or ADRs in your particular circumstances.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>DIVIDENDS AND
  PAYING AGENTS</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>STATEMENT BY
  EXPERTS</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>DOCUMENTS ON
  DISPLAY</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">It is possible to read
  and copy documents referred to and filed with the SEC together with this Form
  20-F at the SEC&#146;s public reference room located at 450 Fifth Street, NW,
  Washington, DC 20549. Please call the United States Securities and Exchange
  Commission at 1-800-SEC-0330 for further information on the public reference
  rooms.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Copies of this Form 20-F
  Report can be downloaded from the Investors pages on www.novonordisk.com (the
  contents of the website are not incorporated by reference into this Form 20-F.)
  The Form 20-F is also filed and can be viewed via EDGAR on <u><font color="#0000ff">www.sec.gov</font></u>.
  </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>SUBSIDIARY INFORMATION</u>
  </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p>&nbsp; </p>
<p><font face="Times New Roman, Times, serif" size="2"><a name="#p24"></a>ITEM
  11 &nbsp;&nbsp;QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISKS </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Financial exposure
  and financial risk management </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">For a description and discussion
  of the Company&#146;s foreign exchange risk management, interest risk management,
  counterparty risk management and equity price risk management, please refer
  to Note 32 and the section on Risk management on pages 110-111 in our <i>Annual
  Report 2006</i>. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Sensitivity analysis
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">When conducting a sensitivity
  analysis, the Group assesses the change in fair value on the market-sensitive
  instruments following hypothetical changes in market rates and prices. The rates
  used to mark-to-market the instruments are market data from the end of 2006.
  </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Interest rate sensitivity
  analysis </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">The financial instruments
  included in the sensitivity analysis of interest rate risk consist of the Group&#146;s
  marketable bonds and deposits together with short- and long-term loans with
  floating and </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">24</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_25"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">fixed interest rates together
  with interest rate swaps and cross currency swaps. Not included are foreign
  exchange forwards, foreign exchange options, and foreign exchange swaps due
  to the very limited interest effect of these instruments when the interest rate
  risk is assessed through the below-mentioned risk measures. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The interest rate risk
  is calculated as the &#145;duration&#146;, which expresses the percentage change
  in the market value of the financial instruments by a 1 percentage point parallel
  shift in the interest rate curve.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">An interest rate change
  has a very limited effect on the Group&#146;s financial instruments. The table
  below shows how a 1 percentage point change of the interest rate level, assuming
  all other variables remain unchanged, impacts the fair value of the Group&#146;s
  financial instruments.</font></p>
<p><font size="2" face="Times New Roman, Times, serif">The result of the sensitivity
  analysis at the end of 2006 is as follows: </font></p>
<table width="100%" border=1 cellspacing=0 cellpadding=0>
  <tr valign="bottom">
    <td>
      <div align="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>
    </td>
    <td align="center" width="40%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Interest
        rate level</b></font></div>
    </td>
    <td align="center" width="40%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Fair
        value of Group&#146;s<br>
        &nbsp;&nbsp;</b></font><font face="Times New Roman, Times, serif" size="2"><b>financial
        instruments</b></font><font face="Times New Roman, Times, serif" size="2"><b><br>
        &nbsp;&nbsp; (DKK million)</b></font></div>
    </td>
  </tr>
  <tr valign="top">
    <td align="center" rowspan="2"><font size="2" face="Times New Roman, Times, serif">2006</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">+
        1 percentage point&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">+53&nbsp;&nbsp;</font></td>
  </tr>
  <tr>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">-
        1 percentage point&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">- 53&nbsp;&nbsp;</font></td>
  </tr>
  <tr valign="top">
    <td align="center" rowspan="2"><font size="2" face="Times New Roman, Times, serif">2005</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">+
        1 percentage point&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">+51&nbsp;&nbsp;</font></td>
  </tr>
  <tr>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">-
        1 percentage point&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">- 51&nbsp;&nbsp;</font></td>
  </tr>
</table>
<p><font face="Times New Roman, Times, serif" size="2"><b>Foreign exchange sensitivity
  analysis </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">The financial positions
  included in the foreign exchange sensitivity analysis are the Group&#146;s cash,
  accounts receivable and payable, short- and long-term loans, short- and long-term
  financial investments, foreign exchange forward contracts, foreign exchange
  options, and foreign exchange swaps hedging transaction exposure. Furthermore,
  interest rate swaps and cross currency swaps are included. Not included are
  anticipated currency transactions, investments and fixed assets. Cross currency
  swaps hedging transaction exposure are excluded from the sensitivity analysis,
  as the effects of changing exchange rates hereon are recognized directly under
  shareholders&#146; funds. Moreover, the Group does not have any marketable bonds
  in foreign currency.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">At the end of 2006, a
  5% increase in the levels of all foreign exchange rates against the DKK, i.e.
  a unilateral weakening of DKK, would, all other variables being unchanged, result
  in a decrease in the fair value of the Group&#146;s financial positions of DKK
  450 million. A 5% decrease in the levels of all foreign exchange rates against
  DKK, i.e. a unilateral strengthening of DKK, would, all other variables being
  unchanged, increase the value of the Group&#146;s financial positions by DKK
  450 million. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In comparison, at the
  end of 2005, a 5% increase in the levels of all foreign exchange rates against
  the DKK, i.e. a unilateral weakening of DKK, would, all other variables being
  unchanged, result in a decrease in the fair value of the Group&#146;s financial
  positions of DKK 398 million. A 5% decrease in the levels of all foreign exchange
  rates against DKK, i.e. a unilateral strengthening of DKK, would, all other
  variables being unchanged, increase the value of the Group&#146;s financial
  positions by DKK 398 million. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">To reflect the Danish
  fixed rate policy vis-&agrave;-vis EUR, an alternative calculation has been
  made. This calculation assumes that DKK remains unchanged versus EUR, i.e. that
  DKK and EUR weaken by 5% against all other currencies. Likewise it is assumed
  that DKK and EUR strengthen by 5% against all other currencies. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">At the end of 2006, a
  5% increase in the levels of foreign exchange rates against DKK and EUR would,
  all other variables being unchanged, result in a decrease in the fair value
  of the Group&#146;s financial positions of DKK 644 million. A 5% decrease in
  the levels of all foreign exchange rates against DKK and EUR would, all other
  variables being unchanged, increase the value of the Group&#146;s financial
  positions by DKK 693 million. </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">25</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_26"></a> </font>
<p><font size="2" face="Times New Roman, Times, serif">In comparison, at the end
  of 2005, a 5% increase in the levels of all foreign exchange rates against the
  DKK and EUR would, all other variables being unchanged, result in a decrease
  in the fair value of the Group&#146;s financial positions of DKK 546 million.
  A 5% decrease in the levels of all foreign exchange rates against DKK and EUR
  would, all other variables being unchanged, increase the value of the Group&#146;s
  financial positions by DKK 570 million.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In order to make the two
  years comparable the figures of 2005 have been adjusted to include interest
  rate swaps and cross currency swaps. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The result of the sensitivity
  analysis at the end of 2006 is as follows: </font></p>
<table width="100%" align="center" border=1 cellspacing=0 cellpadding=0>
  <tr valign="bottom">
    <td>
      <div align="center">&nbsp;&nbsp;&nbsp;&nbsp;</div>
    </td>
    <td align="center" width="30%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Exchange
        rate level<br>
        </b></font><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;(change
        against DKK)</b></font></div>
    </td>
    <td align="center" width="30%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Fair
        value of Group&#146;s <br>
        &nbsp;&nbsp;fi</b></font><font face="Times New Roman, Times, serif" size="2"><b>nancial
        positions </b></font><font face="Times New Roman, Times, serif" size="2"><b>-
        DKK unchanged -</b></font><font face="Times New Roman, Times, serif" size="2"><b>
        <br>
        &nbsp;&nbsp;(DKK million)</b></font></div>
    </td>
    <td align="center" width="30%">
      <div align="center"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Fair
        value of Group&#146;s<br>
        </b></font><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;financial
        positions<br>
        </b></font><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;-
        DKK &amp; EUR unchanged -</b></font><font face="Times New Roman, Times, serif" size="2"><b><br>
        &nbsp;&nbsp;(DKK million)</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="center" rowspan="2" valign="top"><font size="2" face="Times New Roman, Times, serif">2006</font></td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">+
        5 percentage point&nbsp;&nbsp;</font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">-
        450&nbsp;&nbsp;</font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">-644&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">-
        5 percentage point&nbsp;&nbsp;</font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">+
        450&nbsp;&nbsp;</font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">+693&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td align="center" rowspan="2" valign="top"><font size="2" face="Times New Roman, Times, serif">2005</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">+
        5 percentage point&nbsp;&nbsp;</font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">-
        398&nbsp;&nbsp;</font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">-
        546&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">-
        5 percentage point&nbsp;&nbsp;</font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">+
        398&nbsp;&nbsp;</font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">+570&nbsp;&nbsp;</font></div>
    </td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">The asymmetric sensitivities,
  when measuring the change in the fair value of the Group&#146;s financial position
  against both DKK and EUR are caused by the positions in EUR/USD and EUR/JPY
  foreign exchange options. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p26a"></a>ITEM
  12 DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p align="center"> <font face="Times New Roman, Times, serif" size="2"><b><font size="3">PART
  II </font></b> </font></p>
<p>&nbsp; </p>
<p><font face="Times New Roman, Times, serif" size="2"><a name="#p26b"></a>ITEM
  13 &nbsp;&nbsp;DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">None. </font></p>
<p>&nbsp; </p>
<p><font face="Times New Roman, Times, serif" size="2"><a name="#p26c"></a>ITEM
  14 &nbsp;&nbsp;MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND
  USE OF PROCEEDS </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">None. </font></p>
<p>&nbsp; </p>
<p><font face="Times New Roman, Times, serif" size="2"><a name="#p26d"></a>ITEM
  15 &nbsp;&nbsp;CONTROLS AND PROCEDURES</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Evaluation of disclosure
  controls and procedures </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Novo Nordisk maintains disclosure
  controls and procedures that are designed to ensure that information required
  to be disclosed in reports that Novo Nordisk files under the Securities Exchange
  Act of 1934 is recorded, processed, summarized and reported within the time
  periods specified in the rules and forms of the United States Securities and
  Exchange Commission </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">26</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_27"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk&#146;s Chief
  Executive Officer and Chief Financial Officer have evaluated the Company&#146;s
  disclosure controls and procedures as of the end of 2006. Based on this evaluation,
  the Company&#146;s Chief Executive Officer and Chief Financial Officer concluded
  that the Company&#146;s disclosure controls and procedures are effective at
  the reasonable assurance level for gathering, analyzing and disclosing the information
  the Company is required to disclose in the reports it files under the Securities
  Exchange Act of 1934, within the time periods specified in the SEC&#146;s rules
  and forms.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In designing and evaluating
  the disclosure controls and procedures, Management recognized that any controls
  and procedures, no matter how well designed and operated, can provide only reasonable
  assurance of achieving the desired control objectives. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Report of Novo Nordisk
  Management on Internal Control Over Financial Reporting </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Novo Nordisk&#146; Board
  of Directors, the Audit Committee and Executive Management are responsible for
  establishing and maintaining adequate internal control over financial reporting.
  The Novo Nordisk </font><font size="2" face="Times New Roman, Times, serif">Group&#146;s
  internal control system was designed to provide reasonable assurance regarding
  the reliability of financial reporting and the preparation and fair presentation
  of its published consolidated financial statements. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">All internal control systems
  no matter how well designed have inherent limitations. Therefore, even those
  systems determined to be effective may not prevent or detect misstatements and
  can provide only reasonable assurance with respect to financial statement preparation
  and presentation. Also, projections of any evaluation of effectiveness to future
  periods are subject to the risk that controls may become inadequate because
  of changes in conditions, or that the degree of compliance with the policies
  or procedures may deteriorate. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk&#146;s Chief
  Executive Officer and Chief Financial Officer assessed the effectiveness of
  the Group&#146;s internal control over financial reporting as of December 31,
  2006. In making this assessment, they used the criteria established in Internal
  Control &#150; Integrated Framework issued by the Committee of Sponsoring Organizations
  of the Treadway Commission (COSO). Based on this assessment the Chief Executive
  Officer and Chief Financial Officer have concluded that, as of December 31,
  2006, Novo Nordisk Group&#146;s internal control over financial reporting is
  effective based on those criteria. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Management&#146;s assessment
  of the effectiveness of internal control over financial reporting as of De-cember
  31, 2006 has been audited by PricewaterhouseCoopers, Statsautoriseret Revisionsaktieselskab,
  Denmark, an independent registered public accounting firm, as stated in their
  report which is included on page 35. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Changes in internal
  controls over financial reporting </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">There were no changes in
  the Company&#146;s internal control over financial reporting that occurred during
  the year ended 31 December 2006, that have materially affected, or are reasonably
  likely to materially affect the Company&#146;s internal control over financial
  reporting. </font></p>
<p>&nbsp; </p>
<p><font face="Times New Roman, Times, serif" size="2"><a name="#p27"></a>ITEM
  16A &nbsp;&nbsp;AUDIT COMMITTEE FINANCIAL EXPERT </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The Audit Committee has
  three members elected by the board among its members. All members qualify as
  independent as defined by the US Securities and Exchange Commission (SEC). One
  member is designated as chairman and two members have been designated as Audit
  Committee Financial Experts as defined under the Sarbanes-Oxley Act. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The board has in March
  2006 elected the following to the Audit Committee: Kurt Anker Nielsen (Audit
  Committee Chairman and Financial Expert), Niels Jacobsen (Audit Committee Member
  and Financial Expert) and J&oslash;rgen Wedel (Audit Committee Member). </font></p>
<p align="center"><font size="2" face="Times New Roman, Times, serif">27</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_28"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif"><a name="#p28a"></a>ITEM
  16B &nbsp;&nbsp;CODE OF ETHICS </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk has an ethics
  framework consisting of a number of rules and guidelines, including but not
  limited to the Novo Nordisk Way of Management, which consists of the Company&#146;s
  Vision, Charter, commitment to the Triple Bottom Line and Policies as well as
  a business ethics policy and related procedures. This framework is applicable
  to all employees in Novo Nordisk including the Board of Directors and Management.
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The Novo Nordisk Way of
  Management is principle-based and describes corporate values and required mindsets
  on business conduct and ethics including a number of the topics dealt with in
  the rules on Code of Ethics set forth in the Sarbanes-Oxley Act in the New York
  Stock Exchange Listed Company Manual.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk has not established
  a separate Code of Ethics as a response to the requirement set forth in the
  Sarbanes-Oxley Act because the framework is already well integrated in the Company,
  and includes rules and guidelines reasonably similar to those required by Code
  of Ethics in the Sarbanes-Oxley Act and the New York Stock Exchange Listed Company
  Manual.</font></p>
<p><font size="2" face="Times New Roman, Times, serif">For further information
  on the Novo Nordisk Way of Management please visit Novo Nordisk&#146;s home-page
  at <u><font color="#0000ff">www.novonordisk.com</font></u> (The contents of
  the website are not incorporated by reference into this Form 20-F.) </font></p>
<p>&nbsp;</p>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p28b"></a>ITEM
  16C &nbsp;&nbsp;PRINCIPAL ACCOUNTANT FEES AND SERVICES </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Audit fees </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Reference is made to Note
  8 in our <i>Annual Report 2006</i> regarding aggregate audit fees.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Statutory audit</b>
  </font><br>
  <font size="2" face="Times New Roman, Times, serif">Statutory audit fees consist
  of fees billed for the annual audit of the Company&#146;s Annual Report, the
  financial statements of the Parent Company, Novo Nordisk A/S and financial statements
  of fully-owned affiliates including audit of internal controls over financial
  reporting (Sarbanes-Oxley Act Section 404). The fees also include fees billed
  for other audit services, which are those services that only the statutory auditor
  can provide, and include the review of documents filed with the SEC. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Audit-related fees</b>
  </font><br>
  <font size="2" face="Times New Roman, Times, serif">Fees for audit-related services
  consist of fees billed for assurance and related services that are related to
  the performance of the audit or review of the Company&#146;s Annual Report and
  include consultations concerning financial accounting, reporting standards and
  financial due diligence. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Tax fees </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Fees for tax advisory services
  include fees billed for tax compliance services, tax consultations, such as
  assistance and representation in connection with tax audits and appeals, transfer
  pricing and tax planning services. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>All other fees </b>
  </font><br>
  <font size="2" face="Times New Roman, Times, serif">All other fees include fees
  billed for services such as royalty audits and pension plan audits.</font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Pre-approval policies
  </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">The Audit Committee assesses
  and pre-approves all audit and non-audit services provided by PricewaterhouseCoopers.
  The pre-approval includes the type of service and a fee budget. Furthermore,
  the Audit Committee receives a quarterly update on actual services provided
  and fees realized.</font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">28</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_29"></a> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p29a"></a>ITEM
  16D &nbsp;&nbsp;EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Not applicable. </font></p>
<p>&nbsp;</p>
<p><font face="Times New Roman, Times, serif" size="2"><a name="#p29b"></a>ITEM
  16E &nbsp;&nbsp;PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED
  PURCHASERS</font></p>
<table width="100%" align="center" border=1 cellspacing=0 cellpadding=0>
  <tr>
    <td align="center"><font face="Times New Roman, Times, serif" size="2"><b>2006</b></font></td>
    <td align="center" valign="bottom"><font size="2" face="Times New Roman, Times, serif">Total
      Number of<br>
      </font><font size="2" face="Times New Roman, Times, serif">Shares Purchased</font><font size="2" face="Times New Roman, Times, serif"><br>
      (a)</font></td>
    <td align="center" valign="bottom"><font size="2" face="Times New Roman, Times, serif">Average
      Price<br>
      </font><font size="2" face="Times New Roman, Times, serif">Paid per Share
      in<br>
      </font><font size="2" face="Times New Roman, Times, serif">DKK<br>
      </font><font size="2" face="Times New Roman, Times, serif">(b)</font></td>
    <td align="center" valign="bottom"><font face="Times New Roman, Times, serif" size="2">Total
      Number of<br>
      Shares Purchased<br>
      as Part of Publicly<br>
      Announced Plans<br>
      or Programs<br>
      (c)</font></td>
    <td align="center" valign="bottom">
      <p><font face="Times New Roman, Times, serif" size="2">Maximum Approximate<br>
        Value of Shares that<br>
        may yet be purchased<br>
        under the Plans<br>
        or Programs in DKK</font><font face="Times New Roman, Times, serif" size="2"><br>
        (d)</font></p>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;January
        1&#150;31&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">6,000,000,000&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;February
        1&#150;28&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">360,000&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">360.40&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">360,000&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5,870,256,324&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March
        1&#150;31&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">690,000&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">380.55&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">690,000&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5,607,678,402&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;April
        1&#150;30&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5,607,678,402&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May
        1&#150;31&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">320,000&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">372.65&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">320,000&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5,480,998,611&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;June
        1&#150;30&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">190,000&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">354.86&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">190,000&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5,421,007,161&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;July
        1&#150;31&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5,421,007,161&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;August
        1&#150;31&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">5,242,462&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">407,09&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">5,242,462&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">3,287,016,349&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font size="2" face="Times New Roman, Times, serif">September
        1&#150;30&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">666,495&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">430,22&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">666,495&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">3,000,272,205&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;October
        1&#150;31&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">3,000,272,205&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font size="2" face="Times New Roman, Times, serif">November
        1&#150;30&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">3,000,272,205&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;December
        1&#150;31&nbsp;&nbsp;</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">0&nbsp;&nbsp;</font></td>
    <td align="center">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">3,000,272,205&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Total&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>7,468,957&nbsp;&nbsp;</b></font></td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>401,63&nbsp;&nbsp;</b></font></td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>7,468,957&nbsp;&nbsp;</b></font></td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
  </tr>
</table>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Notes to columns (c)
  and (d)</b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">In order to maintain capital
  structure flexibility the Board of Directors will at the Annual General meeting
  on 7 March 2007 also propose a reduction in the B share capital, by cancellation
  of nominally DKK 26.96 million (13,480,000 shares) of current treasury B shares,
  to DKK 539.5 million. This corresponds to a 4% reduction of the total share
  capital. </font></p>
<p align="center">&nbsp; </p>
<p align="center"><font face="Times New Roman, Times, serif" size="2"><b><font size="3">PART
  III </font></b> </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p29c"></a>ITEM
  17 &nbsp;&nbsp;FINANCIAL STATEMENTS </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The financial statements
  required by this item accompany this Annual Report as the Novo Nordisk <i>Annual
  Report 2006</i> (see Exhibit 14.1). </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>NEW US GAAP ACCOUNTING
  PRONOUNCEMENTS</u> </i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Reference is made to Item
  5, New accounting pronouncements.</font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">29</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_30"></a> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><b><i><u>RECONCILIATION
  OF NON-COMPARABLE FINANCIAL MEASURES</u></i></b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In our <i>Annual Report
  2006</i>, Novo Nordisk discloses some financial measures that may not be comparable
  with similarly titled measures of other companies including: </font></p>
<table width="100%" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td valign="top" width="3%"><font face="Times New Roman, Times, serif" size="2">&#149;&nbsp;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">Free
      cash flow;</font></td>
  </tr>
  <tr>
    <td valign="top" width="3%"><font face="Times New Roman, Times, serif" size="2">&#149;&nbsp;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">Cash/earnings;
      and</font></td>
  </tr>
  <tr>
    <td valign="top" width="3%"><font face="Times New Roman, Times, serif" size="2">&#149;&nbsp;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">Return
      on invested capital (ROIC).</font></td>
  </tr>
  <tr>
    <td valign="top" width="3%"><font face="Times New Roman, Times, serif" size="2">&#149;&nbsp;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">Financial
      resources at the end of the year.</font></td>
  </tr>
</table>
<p><font face="Times New Roman, Times, serif" size="2"><b>Free cash flow </b>
  </font><br>
  <font size="2" face="Times New Roman, Times, serif">Free cash flow is defined
  as &#145;cash flow from operating activities plus cash flow from investing activities&#146;
  excluding &#146;Net change in marketable securities (&gt; 3 months)&#146;. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Management uses the measure
  of free cash flow to monitor the operating activities&#146; ability to finance
  the investing activities of the Group. A positive free cash flow shows that
  the operation is able to finance the investing activities of the Group and thus
  external financing is not necessary.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Below is a reconciliation
  of free cash flow &#145;Cash flow from operating activities&#146;. </font></p>
<table width="100%" align="center" border=1 cellspacing=0 cellpadding=0>
  <tr>
    <td align="center" colspan=5>
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Reconciliation
        of free cash flow</b></font></div>

    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td>
      <div align="left">&nbsp;</div>
    </td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td align="center" colspan=2>
      <div align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;DKK
        Million</font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2004&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2005&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2006&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td width="2%">
      <div align="left">&nbsp;</div>
    </td>
    <td align="center" width="69%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;Free
        cash flow</font></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2">4,278&nbsp;&nbsp;</font></div>
    </td>
    <td align="center" width="9%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2">4,833&nbsp;&nbsp;</font></div>
    </td>
    <td align="center" width="8%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2">4,707&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;+</font></div>
    </td>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;Net
        change in marketable securities (&gt;3 months)</font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2">1,310&nbsp;&nbsp;</font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2">(1,032)&nbsp;&nbsp;</font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2">514&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;+</font></div>
    </td>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;Net
        cash used in investing activities</font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2">2,001&nbsp;&nbsp;</font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2">4,911&nbsp;&nbsp;</font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2">2,517&nbsp;&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td>
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;=</b></font></div>
    </td>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Cash
        flow from operating activities</b></font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>7,589&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>8,712&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>7,738&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
</table>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Cash/earnings </b>
  </font><br>
  <font size="2" face="Times New Roman, Times, serif">Cash/earnings is defined
  as &#145;free cash flow as a percentage of net profit&#146;. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Cash/earnings measures
  the Group&#146;s ability to turn earnings into cash and is, therefore, in the
  eyes of Management a meaningful measure for public use to demonstrate a sound
  cash flow development from operations. That is why free cash flow is used as
  the numerator instead of net cash flow, because it is the ability of operations
  to generate cash which should be captured. Cash/earnings is reconciled to &#145;Cash
  flow from operating activities / earnings in %&#146;as follows: </font></p>
<table align="center" border=1 cellspacing=0 cellpadding=0 width="100%">
  <tr>
    <td align="center" colspan=2>
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Reconciliation
        of cash/earnings</b></font></div>
    </td>
    <td width="10%">&nbsp;</td>
    <td width="10%">&nbsp;</td>
    <td width="10%">&nbsp;</td>
  </tr>
  <tr>
    <td width="3%">&nbsp;</td>
    <td>
      <div align="left">&nbsp;</div>
    </td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td align="center" colspan=2>
      <div align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;DKK
        Million</font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2004&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2005&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2006&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Numerator</b></font></div>
    </td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Free
        cash flow</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">4,278<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">4,833<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">4,707<b>&nbsp;&nbsp;</b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Denominator</b></font></div>
    </td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Net
        profit (as reported in Annual Report)</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">5,013<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">5,864<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">6,452<b>&nbsp;&nbsp;</b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right">&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Cash/earnings
        (as reported in Annual Report) in %</b></font></div>
    </td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>85.3%&nbsp;&nbsp;</b></font></td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>82.4%&nbsp;&nbsp;</b></font></td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>73.0%&nbsp;&nbsp;</b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></div>
    </td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Numerator</b></font></div>
    </td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="left">&nbsp;</div>
    </td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="left">&nbsp;</div>
    </td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Free
        cash flow</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">4,278<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">4,833<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>4,707<b>&nbsp;&nbsp;</b></font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>+</font></td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Net
        change in marketable securities (&gt;3 months)</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">1,310<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">(1,032)<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">514<b>&nbsp;&nbsp;</b></font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>+</font></td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Net
        cash used in investing activities</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">2,001<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">4,911<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">2,517<b>&nbsp;&nbsp;</b></font></td>
  </tr>
  <tr>
    <td><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;=</b></font></td>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Cash
        flow from operating activities</b></font></div>
    </td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;7,589&nbsp;&nbsp;</b></font></td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>8,712&nbsp;&nbsp;</b></font></td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>7,738&nbsp;&nbsp;</b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="left">&nbsp;</div>
    </td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Denominator</b></font></div>
    </td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Net
        profit (as reported in Annual Report)</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">5,013<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">5,864<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">6,452<b>&nbsp;&nbsp;</b></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>
      <div align="left">&nbsp;</div>
    </td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Cash
        flow from operating activities</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">7,589<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">8,712<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">7,738<b>&nbsp;&nbsp;</b></font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>/</font></td>
    <td align="center">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Net
        profit (as reported in Annual Report)</font></div>
    </td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">5,013<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">5,864<b>&nbsp;&nbsp;</b></font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">6,452<b>&nbsp;&nbsp;</b></font></td>
  </tr>
  <tr>
    <td><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;=</b></font></td>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Cash
        flow from operating activities / Net profit in %</b></font></div>
    </td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>151.4%&nbsp;&nbsp;</b></font></td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>148.6%&nbsp;&nbsp;</b></font></td>
    <td align="right"><font face="Times New Roman, Times, serif" size="2"><b>119.9%&nbsp;&nbsp;</b></font></td>
  </tr>
</table>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">30</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_31"></a> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Return on invested
  capital (ROIC) </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">ROIC is defined as &#145;operating
  profit after tax (using the effective tax rate) as a percentage of average stocks,
  debtors, tangible and intangible fixed assets less non-interest bearing liabilities
  including provisions (where average is the sum of above assets and liabilities
  at the beginning of the year and at year-end divided by two)&#146;.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">ROIC is used by Management
  as a measure for financial performance. Management believes that ROIC captures
  the Group&#146;s ability to provide a competitive return on investments in the
  Group compared to investing in the capital market.</font></p>
<table width="100%" align="center" border=1 cellspacing=0 cellpadding=0>
  <tr>
    <td align="center" colspan=3>
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Reconciliation
        of ROIC</b></font></div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;</div>
    </td>
    <td width="73%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;&nbsp;</div>
    </td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td align="center" colspan=2>
      <div align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;DKK
        Million</font></div>
    </td>
    <td align="center" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2004&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2005&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>2006&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td align="center" width="73%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td align="center" width="10%">
      <div align="right">&nbsp;</div>
    </td>
    <td align="center">
      <div align="right">&nbsp;</div>
    </td>
    <td align="center" width="10%">
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;</div>
    </td>
    <td align="center" width="73%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;Operating
        profit after tax</font></div>
    </td>
    <td align="center" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>4,691&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>5,759&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>6,420&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;/</b></font></div>
    </td>
    <td align="center" width="73%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;Average
        non-interest bearing balance sheet items</font></div>
    </td>
    <td align="center" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>21,813&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>23,295&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>24,890&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;=</b></font></div>
    </td>
    <td align="center" width="73%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;ROIC
        (as reported in Annual Report) in %</b></font></div>
    </td>
    <td align="center" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>21.5%&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>24.7%&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="center" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>25.8%&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td align="center" width="73%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td align="center" width="10%">
      <div align="right">&nbsp;</div>
    </td>
    <td align="center">
      <div align="right">&nbsp;</div>
    </td>
    <td align="center" width="10%">
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td align="center" colspan="2">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Numerator</b></font></div>
    </td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td align="center" colspan="2">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Reconciliation
        of Operating profit after tax to Operating profit</font></div>
    </td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td width="73%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;</div>
    </td>
    <td align="center" width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Operating
        profit after tax</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">4,691<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">5,759<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">6,420<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>/</font></div>
    </td>
    <td align="center" width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>(1-effective
        tax rate) in %</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">67.2%<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">71.2%<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">70.4%<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;=</b></font></div>
    </td>
    <td align="center" width="73%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Operating
        profit (as reported in Annual Report)</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>6,980&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>8,088&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>9,119&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td>
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td width="10%">&nbsp;&nbsp;</td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;</div>
    </td>
    <td align="center">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Denominator</b></font></div>
    </td>
    <td align="center" width="10%">&nbsp;&nbsp;</td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;</div>
    </td>
    <td align="center" colspan=4>
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Reconciliation
        of Average non-interest bearing balance sheet items to Equity</font></div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;</div>
    </td>
    <td width="73%">
      <div align="left">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;</div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Average
        non-interest bearing balance sheet items as used in ROIC calculation</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">21,813<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">23,295<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">24,890<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>*</font></div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>2</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">43,626<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">46,590<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>49,780<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;</b>-</font></div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Non-interest
        bearing balance sheet items at the beginning of the year</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">21,242<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">22,384<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">24,206<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>=</font></div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Non-interest
        bearing balance sheet items at the end of the year</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">22,384<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">24,206<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">25,574<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;</div>
    </td>
    <td width="73%">
      <div align="left">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;</div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Non-interest
        bearing balance sheet items at the end of the year</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">22,384<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">24,206<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">25,574<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>+</font></div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Investments
        in associated companies</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">883<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">926<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">788<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>+</font></div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Other
        financial assets</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">158<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">169<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">169<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>+</font></div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Marketable
        securities and derivative financial instruments</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">1,341<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">1,722<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">1,833<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>+</font></div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Cash
        at bank and in hand</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">3,433<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">3,303<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">3,270<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;</b>-</font></div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Long-term
        debt</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">(1,188)<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">(1,248)<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">(1,174)<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;</b>-</font></div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Short-term
        debt</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">(507)<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">(1,444)<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">(338)<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;=</b></font></div>
    </td>
    <td width="73%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Equity
        at the end of the year (as reported in Annual Report)</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>26,504&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>27,634&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>30,122&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td width="73%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
    <td>
      <div align="right">&nbsp;</div>
    </td>
    <td width="10%">
      <div align="right">&nbsp;</div>
    </td>
  </tr>
  <tr>
    <td width="3%">
      <div align="left">&nbsp;&nbsp;</div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Operating
        profit (as reported in Annual Report)</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">6,980<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">8,088<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">9,119<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>/</font></div>
    </td>
    <td width="73%">
      <div align="left"><font size="2" face="Times New Roman, Times, serif"><b>&nbsp;&nbsp;</b>Equity</font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">26,504<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">27,634<b>&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font size="2" face="Times New Roman, Times, serif">30,122<b>&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
  <tr>
    <td align="right" width="3%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;=</b></font></div>
    </td>
    <td width="73%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b>&nbsp;&nbsp;Operating
        profit / Equity in %</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>26.3%&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>29.3%&nbsp;&nbsp;</b></font></div>
    </td>
    <td align="right" width="10%">
      <div align="right"><font face="Times New Roman, Times, serif" size="2"><b>30.3%&nbsp;&nbsp;</b></font></div>
    </td>
  </tr>
</table>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">31</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_32"></a> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Financial resources
  at the end of the year </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Financial resources at the
  end of the year is defined as the sum of cash and cash equivalents at the end
  of the year, bonds with original term to maturity exceeding three months and
  undrawn committed credit facilities. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif"></font></p>
<p><font face="Times New Roman, Times, serif" size="2"><a name="#p32"></a>ITEM
  18 &nbsp;&nbsp;FINANCIAL STATEMENTS </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The Registrant has responded
  to Item 17 in lieu of responding to this item. </font></p>
<p>&nbsp; </p>
<p><font face="Times New Roman, Times, serif" size="2">ADDITIONAL INFORMATION
  </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Enforceability of civil
  liabilities </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">The Company is a Danish
  corporation and substantially all of its directors and officers, as well as
  certain independent accountants named herein, are non-residents of the United
  States. A substantial portion of the assets of the Company, its subsidiaries
  and such persons are located outside the United States. As a result, it may
  be difficult for shareholders of the Company to effect service within the United
  States upon directors, officers and independent accountants who are not residents
  of the United States or to enforce judgments in the United States. In addition,
  there can be no assurance as to the enforceability in Denmark against the Company
  or its respective directors, officers and independent accountants who are not
  residents of the United States, or in actions for enforcement of judgments of
  United States courts, of liabilities predicated solely upon the federal securities
  law of the United States.<b> </b> </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">32</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_33"></a> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p33"></a>ITEM
  19 &nbsp;&nbsp;EXHIBITS </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b><u>a. Annual Report</u>
  </b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The following pages from
  our <i>Annual Report 2006</i>, filed on Form 6-K, dated 9 February 2007, are
  incorporated by reference. </font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td>&nbsp;</td>
    <td align="center" width="29%">
      <div align="right"><u><font face="Times New Roman, Times, serif" size="2"><b>Page(s)
        in the Annual Report</b></font></u></div>
    </td>
    <td align="center" width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Business results</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[6-7]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Management report
      and discussion 2006</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[8-15]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Research and development
      pipeline</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[18-19,
      34-35]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Financial highlights</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[52]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Consolidated income
      statements for the years ended 31 December [2004, 2005 and 2006]</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[54]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Consolidated balance
      sheets at 31 December 2005 and 2006</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[55]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Consolidated cash
      flow and financial resources for the years ended 31 December [2004, 2005
      and 2006]</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[56]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Consolidated statements
      of changes in equity for the years ended 31 December [2005 and 2006]</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[57]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Notes to the consolidated
      financial statements</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[58-89]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Note 38, Reconciliation
      to US GAAP</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[88-89]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">List of companies
      in the Novo Nordisk Group</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[100-101]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Summary of financial
      data 2002-2006</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[102-103]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Management Statement</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[105]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Corporate governance</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[108-109]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Risk management</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[110-111]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Board of Directors</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[112-113]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Executive Management</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[114]</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Shareholder information</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif">[115-117]</font></td>
    <td>&nbsp;</td>
  </tr>
</table>
<p> <font face="Times New Roman, Times, serif" size="2"><b>Additional required
  information </b> </font><br>
  <font size="2" face="Times New Roman, Times, serif">Reference is made to note
  19 in our Annual Report for additional information regarding valuation and qualifying
  accounts. </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">33</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_34"></a> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><b><u>b. Exhibits</u>
  </b> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">List of exhibits: </font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr valign="top">
    <td align="center" width="12%">
      <div align="left"><font face="Times New Roman, Times, serif" size="2"><b><u>Exhibit
        No.</u></b></font></div>
    </td>
    <td align="center" width="2%">&nbsp;</td>
    <td align="center" width="56%">
      <div align="left"><u><font face="Times New Roman, Times, serif" size="2"><b>Description</b></font></u></div>
    </td>
    <td align="center" width="2%">&nbsp;</td>
    <td align="center" width="34%">
      <div align="left"><u><font face="Times New Roman, Times, serif" size="2"><b>Method
        of filing</b></font></u></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"></div>
    </td>
    <td align="center">&nbsp;</td>
    <td align="center">
      <div align="left"></div>
    </td>
    <td align="center">&nbsp;</td>
    <td align="center">
      <div align="left"></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">8.1</font></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">List
        of companies in the Novo Nordisk Group</font></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">Incorporated
        by reference to pages 100-101 of our Annual <i>Report 2006 filed on Form
        6-K </i>dated 9&nbsp;February 2007.</font></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"><a href="ex_12-1.htm"><font size="2" face="Times New Roman, Times, serif">12.1</font></a></div>
    </td>
    <td><a href="ex_12-1.htm"></a></td>
    <td>
      <div align="left"><a href="ex_12-1.htm"><font size="2" face="Times New Roman, Times, serif">Certification
        of Lars Rebien S&oslash;rensen, President and Chief Executive Officer
        of Novo Nordisk, pursuant to Section 302 of the Sarbanes-Oxley Act of
        2002.</font></a></div>
    </td>
    <td><a href="ex_12-1.htm"></a></td>
    <td>
      <div align="left"><a href="ex_12-1.htm"><font size="2" face="Times New Roman, Times, serif">Filed
        together with this Form 20-F for 2006.</font></a></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"><a href="ex_12-2.htm"><font size="2" face="Times New Roman, Times, serif">12.2</font></a></div>
    </td>
    <td><a href="ex_12-2.htm"></a></td>
    <td>
      <div align="left"><a href="ex_12-2.htm"><font size="2" face="Times New Roman, Times, serif">Certification
        of Jesper Brandgaard, Executive Vice President and Chief Financial Officer
        of Novo Nordisk, pursuant to Section 302 of the Sarbanes-Oxley Act of
        2002.</font></a></div>
    </td>
    <td><a href="ex_12-2.htm"></a></td>
    <td>
      <div align="left"><a href="ex_12-2.htm"><font size="2" face="Times New Roman, Times, serif">Filed
        together with this Form 20-F for 2006.</font></a></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"><a href="ex_13-1.htm"><font size="2" face="Times New Roman, Times, serif">13.1</font></a></div>
    </td>
    <td><a href="ex_13-1.htm"></a></td>
    <td>
      <div align="left"><a href="ex_13-1.htm"><font size="2" face="Times New Roman, Times, serif">Certification
        pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
        of the Sarbanes-Oxley Act of 2002.</font></a></div>
    </td>
    <td><a href="ex_13-1.htm"></a></td>
    <td>
      <div align="left"><a href="ex_13-1.htm"><font size="2" face="Times New Roman, Times, serif">Filed
        together with this Form 20-F for 2006.</font></a></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">14.1</font></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">Registrant&#146;s
        Annual Report for the fiscal year ended December 2006.</font></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">Incorporated
        by reference to the Registrant&#146;s Report on Form 6-K dated 9&nbsp;February
        2007.</font></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"></div>
    </td>
  </tr>
  <tr valign="top">
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">14.2</font></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">Registrant&#146;s
        Annual Report for the fiscal year ended December 2005.</font></div>
    </td>
    <td>&nbsp;</td>
    <td>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">Incorporated
        by reference to the Registrant&#146;s Report on Form 6-K dated 6&nbsp;February
        2006.</font></div>
    </td>
  </tr>
</table>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">34</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_35"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">Novo Nordisk A/S </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><i>Report of Independent
  Registered Public Accounting Firm</i> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">To the Board of Directors
  and Shareholders of Novo Nordisk A/S: </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">We have completed integrated
  audits of Novo Nordisk A/S&#146;s 2006 and 2005 consolidated financial statements
  and of its internal control over financial reporting as of December 31, 2006,
  and an audit of its 2004 consolidated financial statements in accordance with
  the standards of the Public Company Accounting Oversight Board (United States).
  Our opinions, based on our audits, are presented below. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><u>Consolidated financial
  statements and financial statement schedules</u> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">In our opinion, the consolidated
  financial statements listed in index appearing under Item 19 present fairly,
  in all material respects, the financial position of Novo Nordisk A/S and its
  subsidiaries at De-cember 31, 2006 and December 31, 2005, and the results of
  their operations and their cash flows for each of the three years in the period
  ended December 31, 2006 expressed in Danish kroner and incorporated with reference
  to the Registrant&#146;s Annual Report (the pages listed in item 19 of the Form
  20-F) filed on Form 6-K dated February 8, 2007 in conformity with International
  Financial Reporting Standards. In addition, in our opinion, the financial statement
  schedule listed in the index in item 19 present fairly, in all material respects,
  the information set forth therein when read in conjunction with the related
  consolidated financial statements. These financial statements and financial
  statement schedule are the responsibility of the Company&#146;s management.
  Our responsibility is to express an opinion on these financial statements and
  financial statement schedule based on our audits. We conducted our audits of
  these statements in accordance with the standards of the Public Company Accounting
  Oversight Board (United States). Those standards require that we plan and perform
  the audit to obtain reasonable assurance about whether the financial statements
  are free of material misstatement. An audit of financial statements includes
  examining, on a test basis, evidence supporting the amounts and disclosures
  in the financial statements, assessing the accounting principles used and significant
  estimates made by management, and evaluating the overall financial statement
  presentation. We believe that our audits provide a reasonable basis for our
  opinion. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">International Financial
  Reporting Standards vary in certain significant respects from accounting principles
  generally accepted in the United States of America. Information relating to
  the nature and effect of such differences is presented in Note 38 to the consolidated
  financial statements in the 2006 Annual Report on Form 20-F. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><u>Internal control over
  financial reporting</u> </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Also, in our opinion,
  Management&#146;s assessment, included in Management&#146;s Report on Internal
  Control Over Financial Reporting appearing under Item 15, that the Company maintained
  effective internal control over financial reporting as of December 31, 2006
  based on criteria established in <i>Internal Control - Integrated Framework</i>
  issued by the Committee of Sponsoring Organizations of the Tread-way Commission
  (COSO), is fairly stated, in all material respects, based on those criteria.
  Furthermore, in our opinion, the Company maintained, in all material respects,
  effective internal control over financial reporting as of December 31, 2006,
  based on criteria established in <i>Internal Control - Integrated Framework</i>
  issued by the COSO. The Company&#146;s management is responsible for maintaining
  effective internal control over financial reporting and for its assessment of
  the effectiveness of internal control over financial reporting. Our responsibility
  is to express opinions on management&#146;s assessment and on the effectiveness
  of the Company&#146;s internal control over financial reporting based on our
  audit. We conducted our audit of internal control over financial reporting in
  accordance with the standards of the Public Company Accounting Oversight Board
  (United States). Those standards require that we plan and perform the audit
  to obtain reasonable assurance about whether effective internal control over
  financial reporting was maintained in all material respects. An audit of internal
  control over financial reporting includes obtaining an understanding of internal
  control</font></p>
<p align="center"><font size="2" face="Times New Roman, Times, serif">35</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_36"></a> </font>
<p> <font size="2" face="Times New Roman, Times, serif">over financial reporting,
  evaluating management&#146;s assessment, testing and evaluating the design and
  operating ef</font><font size="2" face="Times New Roman, Times, serif">fectiveness
  of internal control, and performing such other procedures as we consider necessary
  in the circumstances. We believe that our audit provides a reasonable basis
  for our opinions.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">A company&#146;s internal
  control over financial reporting is a process designed to provide reasonable
  assurance regarding the reliability of financial reporting and the preparation
  of financial statements for external purposes in accordance with generally accepted
  accounting principles. A company&#146;s internal control over financial reporting
  includes those policies and procedures that (i) pertain to the maintenance of
  records that, in reasonable detail, accurately and fairly reflect the transactions
  and dispositions of the assets of the company; (ii) provide reasonable assurance
  that transactions are recorded as necessary to permit preparation of financial
  statements in accordance with generally accepted accounting principles, and
  that receipts and expenditures of the company are being made only in accordance
  with authorizations of management and directors of the company; and (iii) provide
  reasonable assurance regarding prevention or timely detection of unauthorized
  acquisition, use, or disposition of the company&#146;s assets that could have
  a material effect on the financial statements.</font></p>
<p> <font size="2" face="Times New Roman, Times, serif">Because of its inherent
  limitations, internal control over financial reporting may not prevent or detect
  misstatements. Also, projections of any evaluation of effectiveness to future
  periods are subject to the risk that controls may become inadequate because
  of changes in conditions, or that the degree of compliance with the policies
  or procedures may deteriorate. </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">30 January 2007<br>
  Copenhagen, Denmark </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">PricewaterhouseCoopers
  </font><br>
  <font size="2" face="Times New Roman, Times, serif">Statsautoriseret Revisionsaktieselskab
  </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">36</font></p>
<hr noshade align="center" width="100%" size=2>
<div style="page-break-before:always"></div>
<font face="Times New Roman, Times, serif" size="2"><page></font>
<p><font face="Times New Roman, Times, serif" size="2"><a href="#contents">Back
  to Contents</a></font></p>
<font face="Times New Roman, Times, serif" size="2"><a name="page_37"></a> </font>
<p> <font face="Times New Roman, Times, serif" size="2"><a name="#p37"></a>SIGNATURES
  </font></p>
<p> <font size="2" face="Times New Roman, Times, serif">The Registrant hereby
  certifies that it meets all of the requirements for filing on Form 20-F and
  that it has duly caused and authorized the undersigned to sign this Annual Report
  on its behalf. </font></p>
<p> <font face="Times New Roman, Times, serif" size="2"><b>NOVO NORDISK A/S </b>
  </font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr valign="top">
    <td colspan=2><font size="2" face="Times New Roman, Times, serif">/s/ Lars
      Rebien S&oslash;rensen</font></td>
    <td align="center" width="2%">&nbsp;</td>
    <td align="center" colspan=2>
      <div align="left"><font size="2" face="Times New Roman, Times, serif">/s/
        Jesper Brandgaard</font></div>
    </td>
  </tr>
  <tr valign="top">
    <td colspan=2>
      <hr noshade size=1>
    </td>
    <td>&nbsp;</td>
    <td colspan=2>
      <hr noshade size=1>
    </td>
  </tr>
  <tr valign="top">
    <td width="8%"><font size="2" face="Times New Roman, Times, serif">Name:</font></td>
    <td width="36%"><font size="2" face="Times New Roman, Times, serif">Lars Rebien
      S&oslash;rensen</font></td>
    <td>&nbsp;</td>
    <td width="8%"><font size="2" face="Times New Roman, Times, serif">Name: </font></td>
    <td width="36%"><font size="2" face="Times New Roman, Times, serif">Jesper
      Brandgaard</font></td>
  </tr>
  <tr valign="top">
    <td width="8%"><font size="2" face="Times New Roman, Times, serif">Title:</font></td>
    <td width="36%"><font size="2" face="Times New Roman, Times, serif">President
      and Chief Executive Officer</font></td>
    <td width="8%">&nbsp;</td>
    <td width="8%"><font size="2" face="Times New Roman, Times, serif">Title:</font></td>
    <td width="36%"><font size="2" face="Times New Roman, Times, serif">Executive
      Vice President and</font></td>
  </tr>
  <tr valign="top">
    <td width="8%">&nbsp;</td>
    <td width="36%">&nbsp;</td>
    <td>&nbsp;</td>
    <td width="8%">&nbsp;</td>
    <td width="36%"><font size="2" face="Times New Roman, Times, serif">Chief
      Financial Officer</font></td>
  </tr>
</table>
<p> <font size="2" face="Times New Roman, Times, serif">Dated: 30 January 2007
  </font></p>
<p align="center"> <font size="2" face="Times New Roman, Times, serif">37</font></p>
<hr noshade align="center" width="100%" size=2>
<noscript><img src="https://www.sec.gov/akam/13/pixel_7b384c2c?a=dD00MDcwZDFjODNhOTkzMjNkMGMyMmM0N2NhMzc2OGM3ZDdhYmU1YzRhJmpzPW9mZg==" style="visibility: hidden; position: absolute; left: -999px; top: -999px;" /></noscript></body>

</html>

</TEXT>
</DOCUMENT>
